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[57] ABSTRACT 
Peptidyl derivatives of diesters of a-aminoalkylphosphonic 
acids with basic substituents, their use in inhibiting serine 
proteases with trypsin-like specificity and their roles as 
anti-inflammatory agents, anticoagulants, and anti-tumor 
agents. 
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This is a continuation-in-part of application Ser. No. 
08/184,286 filed on Jan. 21, 1994, now U.S. Pat. No. 5 
5,686,419. 
chymotrypsin-like enzymes hydrolyze peptide bonds where 
the Pl amino acid is Trp, Tyr, Phe, Met, Leu or other amino 
acid residue which contain an aromatic or large alkyl side 
chain. All of the above enzymes have extensive secondary 
specificity and recognize amino acid residues removed from 
the Pl residue. 
STATEMENT OF GOVERNMENT INTEREST 
This invention was made with government support under 
Grants No. HL34035 and HL29307 awarded by the National 
Heart, Lung and Blood Institute of the National Institutes of 
Health. The government has certain rights in the invention. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
This invention relates to a novel class of peptidyl deriva-
tives of aromatic diesters of a-aminoalkylphosphonic acids 
useful for selectively inhibiting elastase, selectively inhib-
iting chymotrypsin-like enzymes and selectively inhibiting 
trypsin-like enzymes. The diesters of 
a-aminoalkylphosphonic acids are analogues of natural 
a-amino acids. This invention is also relates to a method for 
controlling tumor invasion, treating inflammation and con-
trolling blood coagulation in patients using the novel com-
pounds of the present invention. We have found that peptidyl 
derivatives of aromatic diesters of a-aminoalkylphosphonic 
acids are potent inhibitors of chymotrypsin-like enzymes, 
elastases, blood coagulation enzymes, tryptases, kaliikreins, 
and other serine proteases, and therefore they are useful as 
anti-tumor, anti-inflammatory and anticoagulant agents. 
2. Description of the Related Art 
Serine proteases play critical roles in several physiologi-
It is a further object of this invention to define new 
protease inhibitors, especially inhibitors for chymotrypsin 
10 and chymotrypsin-like enzymes, elastase inhibitors, blood 
coagulation enzyme inhibitors, granzyme inhibitors, and 
tryptase inhibitors. These inhibitors are useful for control-
ling tumor invasion, blood coagulation and various inflam-
matory conditions mediated by serine proteases. The inhibi-
15 tors of this invention would be useful for treating diseases 
such as vascular clotting, inflammations, tumor invasion, 
pancreatitis, emphysema or infantile and adult respiratory 
distress syndrome. The inhibitors of this invention would 
also be useful for controlling hormone processing by serine 
20 proteases and for treating diseases related to tryptases such 
as inflammation and skin blistering. 
It is yet another object of this invention to define a novel 
group of specific inhibitors useful in vitro for inhibiting 
25 trypsin, elastase, chymotrypsin and other serine proteases of 
similar specificity. Such inhibitors could be used to identify 
new proteolytic enzymes encountered in research. They 
could also be used in research and industrially to prevent 
undesired proteolysis that occurs during the production, 
30 isolation, purification, transport and storage of valuable 
peptides and proteins. Such proteolysis often destroys or 
alters the activity and/or function of the peptides and pro-
teins. Uses would include the addition of the inhibitors to 
antibodies, enzymes, plasma proteins, tissue extracts or 
other proteins and peptides which are widely sold for use in 
clinical analyses, biomedical research, and for many other 
reasons. 
These and other objects are accomplished by the present 
invention which defines novel peptidyl derivative of aryl 
diesters of a-aminoalkylphosphonic acids. These phospho-
nate derivatives are potent inhibitors of serine proteases 
including chymotrypsin-like enzymes, trypsin-like 
enzymes, elastase-like enzymes, and other enzymes with 
other substrate specificities. The phosophonates are stable in 
buffer or plamsa, and inhibit the serine proteases to give 
stable inhibited enzyme derivatives. The phosphonates can 
be used both in vitro and in vivo. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Peptidyl derivatives of aryl diesters of 
cal processes such as digestion, blood coagulation, comple- 35 
ment activation, fibrinolysis, and reproduction. Serine pro-
teases are not only a physiological necessity, but also a 
potential hazard if they are not controlled. Blood coagula-
tion serine proteases are responsible for vascular clotting, 
cerebral infarction and coronary infarction. Chymotrypsin- 40 
like enzymes and plasmin are involved in tumor invasion, 
tissue remodeling, and clot dissociation. Uncontrolled pro-
teolysis by other serine proteases such as elastase may cause 
pancreatitis, emphysema, rheumatoid arthritis, inflammation 
and adult respiratory distress syndrome. Accordingly, spe- 45 
cific and selective inhibitors of these proteases should be 
potent anticoagulants, anti-inflammatory agents and anti-
tumor agents useful in the treatment of protease-related 
diseases (Powers and Harper, in Proteinase Inhibitors, Bar-
rett and Salvesen, eds., Elsevier, 1986, pp. 55-152; 50 
Tryggvason, Hoyhtya and Salo, Biochem. Biophys. Acta, 
1987, 907, 191-217, incorporated herein by reference). In 
vitro proteolysis by trypsin, chymotrypsin or the elastase 
family is a serious problem in the production, purification, 
isolation, transport or storage of peptides and proteins. 55 a-aminoalkylphosphonic acids have be found to be excel-
lent inhibitors of several serine proteases including bovine 
thrombin, human factor Xlla, human factor Xa, human 
plasma kallikrein, bovine trypsin, rat skin tryptase, human 
leukocyte elastase, porcine pancreatic elastase, bovine 
BRIEF SUMMARY OF THE INVENTION 
It is an object of this invention to define a novel group of 
specific inhibitors for trypsin, elastase, chymotrypsin, 
granzymes, and other serine proteases. Inhibitors are com-
pounds that can reduce or eliminate the catalytic activity of 
the enzyme. Trypsin and trypsin-like enzymes normally 
cleave peptide bonds in proteins and peptides where the 
amino acid residue on the carbonyl side of the split bond (Pl 
residue) is Lys or Arg. Elastase and elastase-like enzymes 
cleave peptide bonds where the Pl amino acid is Ala, Val, 
Ser, Leu and other similar amino acids. Chymotrypsin and 
60 chymotrypsin, human leukocyte cathepsin G, rat mast cell 
protease II, mast cell tryptase, granzyme A, and granzyme 
K. The diesters of a-aminoalkylphosphonic acids are ana-
logues of natural a-amino acids and are designated by the 
generally accepted the letter abbreviations for the amino 
65 acid followed by the superscript P. For example diphenyl 
a-(N-benzyloxycarbonylanino )ethylphosphonate which is 
related to alanine is abbreviated as Cbz-AlaP(OPh)2 . 
3 
CH3 
I ,.....orh 
Bzl- O-CO- NH-CH-P 
11'-oPh 
0 
Complete Structure of Cbz-AlaP(OPh)2 
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Peptidyl derivatives of aryl diesters of 
a-aminoalkylphosphonic acids inhibit serine proteases by 10 
reaction with the active site serine to form "phosphonylated" 
enzymes, which due to similarity of phosphorus atom to the 
tetrahedral intermediate formed during peptide hydrolysis, 
show remarkable stability. The enzyme catalytic apparatus is 
required to activate the phosphorus atom for nucleophilic 15 
substitution and reaction with enzyme. The activation is 
mainly due to precise interaction with the sl pocket of 
various serine proteases. The following figure shows the 
reaction course of a phosphonate with a serine protease. The 
phosphonate first binds to the enzyme (below left) and then 20 
reacts to form a covalent bond with the active site serine 
residue (below right). Slow aging can take place with loss of 
the phenoxy group (below center). 
H 
,....-OPh 
p 
11'-oPh 
0 
RC0-(4-AmPhGlyl(OPh)2 
H 
,....-OPh 
p 
11'-oPh 
0 
RCO-( 4-AmPhe l(OPh)2 
Additional specificity as well as increased activation 
toward reaction with the enzyme can be introduced into the 
inhibitor molecule by variation of the amino acid sequence 
in the peptide portion of the structure. In fact there is a good 
agreement between the sequence of enzyme substrates such 
as a peptidyl p-nitroanilides and the sequence of an effective 
peptidyl phosphonate inhibitor. The best inhibitors have the 
sequence of the best peptidyl p-nitroanilide substrate for a 
Substrate 
Binding Site 
_fl 
R 
Active Site 
Ser195 
I 
O-H- -His57 
I ,....-OPh 
R-CO-NH-CH-P -
11'-oPh 
0 
Active Site 
_fl 
Ser195 
RI I H-His57 
,....a 
R-CO-NH-CH-P 
Aging 
11'-oPh 
,0, 
H' 'H 
-
I I oxyanion 
N N hole 
Active Site 
_fl 
Ser195 
RI I H-His57 
,....a 
R-CO-NH-CH-li'-o-
,0, 
H' 'H 
I I oxyanion 
N hole N 
Peptides with a C-terminal phosphonate residue which is 
an analog of valine {e.g. ValP(OPh)2} are potent and specific 
irreversible inhibitors of elastase and elastase-like enzymes. 
The peptides with C-terminal phosphonate residues related 
25 particular enzyme. For example, the best inhibitor for chy-
motrypsin and chymotrypsin-like enzymes is Suc-Val-Pro-
PheP(OPh)2 which has an amino acid sequence that is 
analogous to Suc-Val-Pro-Phe-NA, an excellent substrate 
30 for these enzymes. With human leukocyte elastase, the two 
best inhibitors {MeO-Suc-Ala-Ala-Pro-ValP(OPh)2 and 
Boc-Val-Pro-ValP(OPh)2} have an amino acid sequence 
similar to MeO-Suc-Ala-Ala-Pro-Val-NAand Boe-Val-Pro-
Val-NA, two excellent substrates for this enzyme. For 
35 bovine thrombin, the best phosphonate inhibitor is diphenyl 
Bo c-D -Phe -Pro - amino ( 4- am idin op hen yl) 
methanephosphonate hydrochloride, which corresponds to 
Boc-D-Phe-Pro-Arg-NA, which is excellent substrate for 
40 thrombin, and D-Phe-Pro-Arg-H which is an excellent pep-
tide aldehyde inhibitor of thrombin and an anticoagulant 
(Bajusz, S., Szell, E., Bagdy, D., Barabas, E., Horvath, G., 
Dioszegi, M., Fittler, Z., Szabo, G., Juhasz, A., Tomori, E., 
and Szilagyi, G., J. Med. Chem. 33, 1729-1735 (1990) 
45 incorporated by reference). Since good substrate sequences 
are known in the literature for other serine proteases, it is 
possible to predict the structure of additional excellent 
phosphonate inhibitors for these enzymes {Mammalian 
50 Proteases, A Glossary and Bibliography, Vol. 1 
Endopeptidases, Academic Press, Barrett, A. J., and 
McDonald, J. K. eds, pp. 1-416, 1980; Mammalian 
Proteases, A Glossary and Bibliography, Vol. 2 
Exopeptidases, Academic Press, Barrett, A. J., and 
55 McDonald, J. K. eds, pp. 1-357, 1986; Lottenberg, R., 
to phenylalanine, other aromatic amino acids or amino acids 
with long aliphatic side chains are potent and specific 
inhibitors of chymotrypsin and chymotrypsin-like enzymes. 60 
The peptides with C-terminal phosphonate residues related 
Christensen, U., Jackson, C. M., and Coleman, P. L., Meth-
ods in Enzymology 80, 341-361 (1981) the preceding 
articles are incorporated herein by reference}. It is also 
possible to design good phosophonate inhibitors for serine 
proteases based on the peptide sequences found in other 
potent reversible and irreversible inhibitors for those same 
serine proteases reported in the literature {Powers and 
Harper, in Proteinase Inhibitors, Barrett and Salvesen, eds., 
Elsevier, 1986, pp. 55-152; Trainor, D. A., Trends in Pharm. 
Sci. 8, 303-307 (1987) the preceding articles are incorpo-
rated herein by reference}. 
to ornithine, lysine, arginine or containing a C-terminal 
diphenyl ester of l-amino-1-(4-amidinophenyl) 
methanephosphonate {(4-AmPhGlyt(OPh)J or l-amino-
1-( 4-amidinophenylmethyl)methanephosphonate { ( 4- 65 
AmPhet(OPh)J are specific and potent inhibitors of 
trypsin and trypsin-like enzymes. 
5,952,307 
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Examples of phosphonate inhibitors for various enzymes 
are given below: 
Cbz-Gly-Leu-PheP(OZ)(Z1) 
MeO-Suc-Ala-Ala-Pro-MetP(OZ)(Z1)(SEQ ID NO: 1) 
Suc-Pro-Leu-PheP(OZ)(Z1) and Boc-Ala-AlaPheP(OZ)(Z1) 
Boc-Gly-Leu-PheP(OZ)(Z1), Suc-Phe-Leu-PheP(OZ)(Z1) 
Boc-Ala-Ala-GluP(OZ)(Z1) 
Cbz-Gly-Gly-ProP(OZ)(Z1) 
Ala-ProP(OZ)(Z1) 
Suc-Ala-Ala-Pro-ValP(OZ)(Z1)(SEQ ID NO: 2) 
Suc-Lys(Cbz)-Val-Pro-ValP(OZ)(Z1), 
adamantyl-SOr Lys-(COCH2 CH2 C02H)-Ala-ValP(OZ)(Z1), 
adamantyl-CH2 CH2 0CO-Glu(O-t-Bu )-Pro-ValP (OZ)(Z1 ), 
adamantyl-SOo-Lys(CO-C6H4C02H)-Ala-ValP(OZ)(Z1) 
Suc-Ala-Ala-Pro-LeuP(OZ)(Z1)(SEQ ID NO: 3) 
Glu-Phe-X and Dns-Ala-Phe-X 
D-Val-Gly-X and Dns-Glu-Gly-X 
Cbz-Phe-X and Cbz-Trp-X 
Cbz-Lys-X 
Cbz-Gly-X 
Cbz-Ile-Ala-Gly-X 
Glu-Gly-X 
Dns-Phe-Pro-X 
Dns-Ile-Pro-X 
Cbz-Trp-X 
Cbz-Gly-X 
Cbz-Phe-X 
Cbz-Phe-Gly-X 
for cathepsin G and RMCP II 
for Cathepsin G 
for RMCP I 
for human and dog 
skin ch ymase 
for S. aureus V-8 protease 
for human prolyl 
endopeptidase 
for OPP IV 
for PPE 
for human leukocyte 
(neutrophil) elastase 
for elastolytic proteinase 
from "Schistosoma mansoni'' 
for plasmin 
for factor Xa 
for procine pancreatic 
and human plasma kallikreins 
for human skin tryptase 
for human lung tryptase 
for factors !Xa, Xa, Xia, Xlla 
and bovine plasma kallikrein 
for urokinase 
for plasminogen activator 
for activated protein C 
for bovine factor !Xa 
for bovine factor Xa and Xia 
for bovine factor Xlla 
for trypsin 
6 
where Z represents an aryl group, a substituted aryl group or 
a highly fluorinated alkyl group, and Z1 represents 
perfluoroalkoxy, a substituted aryloxy group, alkoxy, or 
halogen, and X represents Arg1'(0Z)(Z1), OmP(OZ)(Z1), 
LysP(OZ)(Z1), an aryl diester of a-amino-a-(4-
amidinophenyl)methanephosphonate { abbreviated NH2-
CH(AmPh)PO(OZ)(Z1) or 4-AmPhGlyP(OZ)(Z1)}, or 
l-amino-1-( 4-amidinopheny lmethyl)methanephosphonate 
{abbreviated NH 2-CH(AmPhCH2)PO(OZ)(Z1) or 
4-AmPheP(OZ)(Z1)}. 
Diphenyl esters of a-aminoalkylphosphonate can be syn-
thesized by a previously described method (Oleksyszyn et 
35 al., 1979, Synthesis, 985 incorporated by reference). 
Di(substituted phenyl)esters of a-aminoalkylphosphonate 
can also be prepared by the same procedure using tris 
(substituted phenyl) phosphite instead of triphenyl phos-
phite. Perfluoroallyl diesters can be synthesized by a method 
The inhibitory potency of peptidyl derivatives of aryl 
diesters of a-aminoalkylphosphonic acids is also determined 
40 involving transesterification (Szewczyk et al., Synthesis, 
1982, 409-414 incorporated by reference). Alternatively, the 
synthesis of diesters of a-aminoalkylphosphonic acids and 
their peptides can be performed by esterification of the 
phosphonic acid moiety as described previously (Bartlett et 
45 
al., Bioorg. Chem., 1986, 14, 356-377 incorporated by 
reference). 
by the electronic property of the Z group. More electron 
withdrawing groups such as nitro, cyano, halogen, etc. on 
the aryl ring can make the phosphorus atom in the inhibitor 
more electrophilic and accelerate reaction with the active 
site serine of the serine protease. Reactivity toward serine 
proteases can also be obtained by using derivatives where 
the Z groups are highly fluorinated alkyl groups. However 50 increased reactivity can also result in low chemical stability 
and in extreme cases, compounds may be too hydrolytically 
unstable for practical purposes if the Z group is too elec-
tronegative. Phosphonates where the Z group is not suffi-
ciently electron withdrawing will be chemically very stable 
and will react very slowly with serine proteases or not at all. 55 
Such non-reactive inhibitors would include derivatives 
where OZ and Z1 are simple alkoxy groups (e.g. peptidyl 
derivatives of alkyl diesters of a-aminoalkylphosphonic 
acids). Thus the phosphonate ester groups (Z) should rep-
resent a balance between these two competing factors and 60 
we find that diphenyl esters (Z=Ph, Z1=0Ph) are one way 
to obtain a balance between increased reactivity and stability 
in solution. 
The Z1 group can be replaced by either a halide or a cl-6 
alkoxy and still retain inhibitory potency. The alkoxy deriva- 65 
tives tend to be less reactive while the halide derivatives are 
more reactive with serine proteases. 
Monoalkyl monophenyl ester derivatives such as RCO-
AAP(OPh)(OEt) can be prepared by tranesterification 
(example 29) from RCO-AAP(OPh)2. Halide derivatives 
can be prepared by hydrolysis of the diphenyl esters RCO-
AAP (0Ph)2 to the monoester RCO-AAP(OPh)(OH) 
(example 30). This can be converted to the chloride RCO-
AAP(OPh)(Cl)by reaction with thionyl chloride and other 
similar reagents. Reaction with KF would give the fluoride. 
The synthesis of AmPhGlT(0Ph)2 derivatives is illus-
trated in the following figure. 
CN 
0 ¢ )l P(OPh)3 a BzlO NH2 + + -
CHO 
5,952,307 
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-continued 
CN 
0 
BzlO)lN 
H 
/OPh 
hp......_ 
o7 OPh 
NH2 
0 
BzlO)lN 
/OPh 
hp......_ 
H o 7 OPh 
Z-(4-AmPhGlyl(OPh)2 
NH2 
b, c 
-
d 
-
NH2 
5 
10 
15 
20 
25 
8 
hydrolysis after several days (monitored by 31P NMR). 
Furthermore, they show excellent stability in human plasma. 
For example Suc-Val-Pro-PheP(OPh)2 has a hydrolysis half-
time in human plasma of about 20 hrs. These experiments 
demonstrate that the phosphonate inhibitors are remarkably 
stable in buffer and plasma. Thus they can be used under a 
variety of conditions. Phosphonates have the additional 
advantage of being very stable in plasma and will have a 
high effectiveness in vivo due to their long lifetimes. 
Additionally, the inhibitor-enzyme complex is very stable 
and the enzyme did not regain any activity after several 
hours in the case of chymotrypsin and after several days no 
recovery of activity was observed in the cases of elastases 
and trypsin. These experiments show that it is possible to 
decrease or eliminate the enzyme activity and biological 
function of serine proteases for extended time periods. 
Either racemic mixtures of the diphenyl 
a-aminoalkylphosphonate residue or pure diastereomers can 
be used in the inhibitor structures. The racemic compounds 
are more easily synthesized and are obtained from less 
expensive starting materials. The pure optically active 
a-aminoalkylphosphonate derivatives required in the syn-
thesis are more difficult to synthesize (Kafarski et al., Can. 
J. Chem. 1983, 61, 2425) and require more expensive 
starting materials. In the case of the peptidyl phosphonate 
inhibitors which are mixtures of two diastereomers, only one 
will usually react with the enzymes. The pure diastereomers 
will possess higher inhibition rates and could be used at 
lower concentrations. 
H-(4-AmPhGlyl(OPh)2•HCl 
e 
-
RCO-N 
H 
/OPh 
p 
ll'oPh 
0 
"Reagents: (a) AcOH, 60-96' C., 2h; (b) dry HCl in 
CHCl3/ethonol; (c) dry NH3 in CH30H; (d) 2N HCl in CH30H, 
Pd/C; (e) RCOOH, CD! 
Peptidyl derivatives of aryl diesters of 
30 
a-aminoalkylphosphonates may be used in vivo to treat 
diseases resulting from abnormal or uncontrolled blood 
coagulation or diseases caused by uncontrolled proteolysis 
by elastase, chymotrypsin, trypsin and related serine pro-
teases. These inhibitors may be used in vitro to prevent 
35 proteolysis which occurs in the process of the production, 
isolation, purification, storage or transport of peptides and 
proteins. 
Peptide derivatives of 4-amidinophenylglycine phospho-
nate diphenyl ester were prepared using the reactions outline 
The novel peptidyl derivatives of aryl diesters 
a-aminoalkylphosphonates of the present invention have the 
40 following structural formula: 
A compound of the formula: 
R 
~/oz 
X-AA3-AA2-N P 
H 11'z1 
0 
or a pharmaceutically acceptable salt, wherein: 
R is selected from the group consisting of phenyl substi-
tuted with B, benzyl substituted with B on the phenyl ring, 
and C1_6 alkyl substituted with B, 
B is selected from the group consisting of amidino 
{-C(=NH)NH2}, guanidino {-NH-C(=NH)NH2}, 
isothiureido {-S-C(=NH)NH2}, and amino, 
Z is selected from the group consisting of C1_6 
perfiuoroalkyl, phenyl, phenyl substituted with J, phenyl 
disubstituted with J, and phenyl trisubstituted with J, 
Z1 is selected from the group consisting of cl-6 
perfiuoroalkoxy, phenoxy, phenoxy substituted with J, phe-
noxy disubstituted with J, phenoxy trisubstituted with J, cl-6 
alkoxy, and halogen, 
in scheme shown above. The parent compound Z-( 4-
AmPhGlyt(OPh)2 was prepared by a-amidoalkylation of 
triphenyl phosphite with 4-cyanobenzaldehyde and benzyl 
carbamate (60--90° C.,AcOH, 2 h) to give Z-(4-CN-PhGlyt 
(0Ph)2 (70%) which was converted to the iminoester (dry 45 
HCl in CHC13/ethanol) and then to the amidine derivative 
Z-(4-AmPhGlyt(OPh)2 (dry NH3 in methanol, 70-80%). 
Hydrogenolysis of Z-( 4-AmPhGlyt(OPh)2 gave H-( 4-
AmPhGlyt(OPh)2 (60-80%) which was then coupled 
respectively with Z-Pro-OH, Boc-D-Phe-Pro-OH, and 50 
2-NpS02-Gly-OH using CDI to give Z-Pro-(4-AmPhGlyt 
(0Ph)2 Boc-D-Phe-Pro-(4-AmPhGlyt{OPh)2 (29%) and 
2-NpS02-Gly-( 4-AmPhGlyt{OPh)2 (30%). Deblocking 
gave D-Phe-Pro-(4-AmPhGly) (0Ph)2 (24%). The 
4-amidinophenylalanine phosphonate diphenyl ester deriva- 55 
tive Z-( 4-AmPhe )P(OPh) 2 was synthesized from 
4-cyanophenylacetaldehyde using the same reaction scheme 
with slightly modified conditions (a-amidoalkylation, 
25-35%; amidination sequence, 50-70%). Hydrogenolysis 
produced H-(4-ArnPhet(OPh)2 (85-90%) which was 
coupled with Boc-D-Phe-Pro-OH to give Boc-D-Phe-Pro- 60 
(4-AmPhet(OPh)2 (59%). Z-Pro-(4-AmPhet{OPh)2 was 
obtained as a transesterification product during the amidi-
nation of Z-Pro-(4-CN-Phet(OPh)2 (50%). Deblocking of 
with dry HC1/CHC13 produced D-Phe-Pro-(4-AmPhet 
(0Ph)2 (80%). 
J is selected from the group consisting of halogen, C1_6 
65 alkyl, C1_6 perfiuoroalkyl, C1_6 alkoxy, N02, CN, OH, 
C02H, amino, C1_6 alkylarino, C2_12 dialkylamino, C1_6 
acyl, C1_6 alkoxy-CO-, and C1_6 alkyl-S-, 
The diphenyl phosphonate moiety is very resistant to 
chemical hydrolysis and at pH 7.5 we did not observe any 
5,952,307 
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AA3 and AA2 are the same or different and are selected 
from the group consisting of 
(a) a single bond, and 
10 
With elastase-like enzymes which prefer Val, Ser, or Ala at 
the Pl position of their substrates, -ValP-, -Ser-, and-AlaP-
residues would be suitable phosphonate residues to incor-
porate in the Pl position of an inhibitor. Likewise with (b) a blocked or unblocked amino acid residue with the L 
or D configuration at the a-carbon selected from the 
group consisting of alanine, valine, leucine, isoleucine, 
praline, methionine, methionine sulfoxide, 
phenylalanine, tryptophan, serine, threonine, cysteine, 
tyrosine, asparagine, glutamine, aspartic acid, glutamic 
acid, lysine, arginine, histidine, phenylglycine, 
norleucine, norvaline, alpha-aminobutyric acid, 
citrulline, hydroxyproline, ornithine, homolysine, and 
homoarginine, and 
5 trypsin-like enzyme -LysP- or -Ar~- residues would be 
suitable. Unnatural blocked or unblocked alpha amino acid 
residues can also be used in the design of phosphonate 
inhibitors. If the target serine protease will hydrolyze a 
substrate containing the unnatural amino acid residue at the 
(c) glycine, sarcosine, epsilon-aminocaproic acid, and 
beta-alanine, 
10 
Pl position or if an inhibitor structure contains the unnatural 
amino acid residue as the Pl residue, then this residue can 
be used in the design of a phosphonate inhibitor. For 
example, chymotrypsin hydrolyzes para-
fiuorophenylalanine containing substrates and thus the 
-HN-CH(CH2C6H4F)-P(O)- would be suitable for 
X is selected from the group consisting of Y-C- and 
Y-S02-, 
Y is selected from the group consisting of 
(a) C 6H 5 -CH=CH-, (2-furyl)-CH=CH-, 
(2-thienyl)-CH=CH-, and (2-pyridyl)-CH=CH-, 
(b) cl-6 alkenyl substituted with a heterocyclic group, 
15 incorporating into a chymotrypsin inhibitor. Likewise, 
trypsin will hydrolyze substrates with aminoethylcysteine 
residues and cathespin G will hydrolyze aminopropylcys-
teine residues and thus -HN-CH(CH2SCH2CH2NH2)-
P(O)- and-HN- CH(CH2SCH2CH2CH2NH2)-P(0)-
(c) C1_6 alkenyl substituted with the group consisting of 
phenyl, phenyl substituted with K, phenyl disubstituted 
20 would respectively be suitable residues to incorporate into 
inhibitors for trypsin and cathepsin G. One skilled in the art 
of designing inhibitors for proteolytic enzyme can list many 
other unnatural amino acid residues which could be used in 
with K, phenyl trisubstituted with K, naphthyl, naph- 25 
thyl substituted with K, naphthyl disubstituted with K, 
and naphthyl trisubstituted with K, 
(d) 2-phenoxyphenyl and 3-phenoxyphenyl, 
(e) Phenyl substituted with the group consisting of 
phenoxy, phenoxy substituted with K, phenoxy disub- 30 
stituted with K, phenoxy trisubstituted with K, 
naphthyloxy, naphthyloxy substituted with K, naphthy-
loxy disubstituted with K, and naphthyloxy trisubsti-
tuted with K, and 
K is selected from the group consisting of halogen, C1_6 35 
alkyl, C1_6 perfiuoroalkyl, C1_6 alkoxy, N02, CN, OH, 
C02H, amino, C1_6 alkylamino, C2_12 dialkylamino, C1_6 
acyl, C1_6 alkoxy-CO-, and C1_6 alkyl-S-. 
The blocking groups which may be present on -HN-
CH(R)-P(O)- or on the amino acids AA3 and AA2 are 40 
those well known in the art of peptide synthesis. For 
example, a listing of suitable peptide blocking groups is 
found in Gross et al., eds. The Peptides, Vol. 3 (Academic 
Press, New York, 1981). The particular choice of the block-
ing group used in the compounds of the invention depends 45 
on several factors, including the blocking group's affect on 
enzyme specificity, its affect on phosphonate solubility, and 
its utility during synthesis. Suitable blocking groups include 
but are not limited to carbobenzyloxy (Cbz), benzoyl, 
t-butyloxycarbonyl (Boe), glutaryl, p-tolylsulfonyl (Tos), 50 
methoxysuccinyl (MeO-Suc), and succinyl. 
The -HN-CH(R)-P(O)- residue is derived from a 
blocked or unblocked alpha amino acid residue -HN-CH 
(R)-CO- whose alpha carbonyl group has been replaced 
the design of suitable inhibitors. 
Other aryl diesters of a-aminoalkylphosphonic acids have 
been prepared earlier for other purposes (illustrative 
examples: Oleksyszyn, J. et al., Synthesis, 1979, 985-986; 
Vo-Quang, Y. et al., J. Med. Chem. 1986, 43, 579-581; 
Kafarski, P. et al., Tetrahedron, 1987, 43, 799-803; 
Szewczyk, J. et al., Synthesis, 1982, 409-414; the preceding 
articles are incorporated herein by reference). 
A few other derivatives of a-aminoalkylphosphonic acids 
have been prepared recently for inhibition of serine 
proteases, but they are not peptidyl derivatives or are pep-
tidyl derivatives with the phosphonic acid moiety inside the 
peptide chain (Bartlett et al., Bioorg. Chem., 1986, 14, 
356-377.; Lamden et al., Biochem. Biophys. Res. 
Commun., 1983, 112, 1085-1090; the preceding articles are 
incorporated herein by reference). We have published some 
of our work in a paper "Irreversible Inhibition of Serine 
Proteases by Peptidyl Derivatives of 
a-Aminoalkylphosphonate Diphenyl Esters", Oleksyszyn 
and Powers, Biochem. Biophys. Res. Commun. 161, 
143-149 (May 30, 1989 issue). Subsequently, Fastrez et al., 
Tetrahedron Lett., 1989, 30, 6861-6864 reported phospho-
nate inhibitors similar to those which we reported and which 
we describe in this specification (both the preceding articles 
are incorporated herein by reference). Many other examples 
are given in the tables. 
The following compounds are representative of but do not 
limit the invention: 
Diphenyl amino( 4-amidinophenyl)methane-phosphonate 
dihydrochloride {abbreviated NH2-CH(Am-C6H4)PO 
(0Ph)2 or (4-AmPhGlyt(OPh)2} 
Diphenyl N-benzyloxycarbonylamino( 4-amidinophenyl) 
methanephosphonate hydrochloride {abbreviated Cbz-
NH-CH(Am-C6H4)P0( 0Ph)2, or Cbz-(4-AmPhGlyt 
(OPh)2} 
by a P(O) group. The R group is the side chain of the alpha 55 
amino acid. The alpha amino acid residue is derived from 
natural alpha amino acids such as those listed in the IUPAC-
IUB Joint Commission on Biochemical Nomenclature 
report on the Nomenclature and Symbolism for Amino 
Acids and Peptides (J. Biol Chem., 260, 14-42 (1985) 
incorporated by reference). The choice of the particular 
amino acid residue used in the design of the phosphonate 
inhibitor will depend on the enzyme targeted for inhibition. 
For example, with chymotrypsin-like enzymes which prefer 
Trp, Tyr, or Phe at the Pl position of their substrates, -TrpP-, 65 
-Tyr-, and -PheP- residues would be suitable phosphonate 
residues to incorporate into the Pl position of an inhibitor. 
60 Diphenyl N-(N-benzyloxycarbonylprolyl)amino( 4-
amidinophenyl)methanephosphonate hydrochloride 
{abbreviated Cbz-NH-Pro-NHCH(Am-C6H4)PO(OPh)2 
or Cbz-Pro-( 4-AmPhGlyt(OPh)2} 
Di phenyl N-(D-Phe-Pro )amino( 4-amidinophenyl) 
methanephosphonate dihydrochloride (abbreviated 
D-Phe-Pro-NHCH(Am-C6H4)PO(OPh)2 or D-Phe-Pro-
( 4-AmPhGlyt(OPh)2} 
5,952,307 
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Diphenyl N-(Boc-D-Phe-Pro )amino( 4-amidinophenyl) 
methanephosphonate hydrochloride {abbreviated Boc-D-
Phe-Pro-NHCH(Am-C6H4)P0( 0Ph)2 or Boc-D-Phe-L-
Pro-( 4-AmPhGlyt(OPh)2} 
12 
plots of Inv /v 0 vs time, and the correlation coefficients were 
greater then 0.98. 
Diphenyl N-(N- ~-napthylsulfonylglycyl)amino( 4- 5 
amidinophenyl)methanephosphonate hydrochloride 
{abbreviated naphthylsulfonyl-Gly-NHCH(Am-C6H4) 
PO(OPh)2 or 2-NpS02-Gly-(4-AmPhGlyt{OPh)2} 
Anticoagulants can prolong the clotting time of human 
plasma and play important roles in the treatment of blood 
coagulation related diseases such as vascular clotting, cere-
bral infarction and coronary infarction (Williams et al., 
Hematology, 3rd ed. McGraw Hill, 1983 and Ingram et al., 
Bleeding Disorders, 2nd ed. Blackwell Scientific 
Publications, 1985). These two books are incorporated Cbz-( 4-AmPhe t(OPh)2 
( 4-AmPhe t ( 0 Ph )22H Cl 
Cbz-Pro-( 4-CN-Phe t(OPh)2 
Cbz-Pro-(4-AmPhet(OEt)2 
Boc-D-Phe-Pro-( 4-CN-Phe t(OPh)2 
Boc-D-Phe-Pro-(4-AmPhet(OPh)2 
D-Phe-Pro-( 4-AmPhe t(OPh)2 
Boc-Phe-Phe-(4-AmPhGlyt(OPh)2 
Cbz-Thr-( 4-AmPhGlyt(OPh)2 
Boc-Leu-Thr-( 4-AmPhGlyt(OPh)2 
( 4-AmPhGlyt{OPh-4-Cl)2, 
Z-( 4-AmPhGlyt(OPh4-Cl)2. 
Cinnamoyl-( 4-AmPhGlyt(OPh)2, 
3-(2-Furyl)acryloyl-( 4-AmPhGlyt( 0Ph)2, 
3-(3-Thienyl)acryloyl-( 4-AmPhGlyt( 0Ph)2, 
3-(2-Pyridyl)acryloyl-( 4-AmPhGlyt( 0Ph)2, 
2-Phenoxybenzoyl-( 4-AmPhGlyt(OPh)2, 
3-Phenoxybenzoyl-( 4-AmPhGlyt(OPh)2, 
2-Phenoxybenzoyl-Pro-(4-AmPhGlyt(OPh)2, 
3-Phenoxybenzoyl-Pro-(4-AmPhGlyt(OPh)2, 
2-Phenoxybenzoyl-Pro-LysP(OPh)2, 
3-Phenoxybenzoyl-Pro-LysP(OPh)2, 
2-Phenoxybenzoyl-Pro-HomoLysP(OPh)2, and 
3-Phenoxybenzoyl-Pro-HomoLysP(OPh)2. 
It has been found that compounds of the present invention 
have potent antiprotease activity as shown in Table I, Table 
II, and Table III by effective inhibition of human granzyme 
A, rat granzyme A, rat granzyme K, mast cell tryptase, 
bovine trypsin, human thrombin, factor Xa, plasmin, and 
urokinase. It has been found that compounds of the present 
invention have anticoagulant activity as shown in Table II 
and Table III by effective inhibition of the proteolytic 
function of blood coagulation enzymes in Hepes buffer. It 
has also been found that compounds of the present invention 
have anti-tumor activity as shown in Table III by effective 
inhibition of the proteolytic function of trypsin-like enzymes 
plasmin and urokinase. 
Inactivation rates of serine proteases by aryl diesters of 
peptidyl derivatives of a-aminoalkylphosphonates were 
measured by the incubation method. An aliquot of inhibitor 
(25 or 50 µl) in Me2SO was added to a buffered enzyme 
solution (0.01-2.3 µM) to initiate the inactivation. Aliquots 
(50 µl) were withdrawn at various intervals and the residual 
enzymatic activity was measured. Me2SO concentration in 
the reaction mixture was 8-12% (v/v).A0.1MHEPES,0.01 
M CaC12, pH 7.5 buffer was utilized for trypsin and trypsin-
like enzymes. A 0.1 M HEPES, 0.5 M NaCl, pH 7.5, was 
utilized for the other serine proteases. The inhibitor concen-
trations are shown in the Tables I, II, and III. Peptide 
thioesters or peptide nitroanilides with the appropriate 
sequences were used as substrates for various serine pro-
teases. All peptide thioesters hydrolysis rates were measured 
with the assay mixture containing 4,4'-dithiodipyridine 
{ E324=19800 M-1cm-1; Grasetti & Murray, Arch. Biochem. 
Biophys. 1967, 119, 41-48}. Peptide 4-nitroanilide hydroly-
10 herein by reference. The presence of certain inhibitors of this 
invention in the human plasma would prolong the prothrom-
bin time, thus these inhibitors would act as anticoagulant in 
vivo. Currently, there are a few anticoagulant drugs in use 
clinically, and the inhibitors described in this invention can 
15 be used as anticoagulants in the treatment of animals. 
The activity of some proteases correlate directly with the 
invasiveness of tumor cells {Nakajima, M. et al., Science, 
1983, 220, 611-613; Sloane, B. F. et al., Cancer Res. 1982, 
42, 980-987 and these two articles are incorporated herein 
20 by reference}. The tumor invasion can be stopped by treat-
ment with inhibitors of serine proteases {Tryggvason, K. et 
al., Biochem. Biophys. Acta, 1987, 907, 191-217, and this 
article is incorporated herein by reference}. Thus the novel 
inhibitors showed in Table I, Table II, and Table III will be 
25 useful for treatment of tumors. 
For treatment of blood coagulation-related diseases, 
tumor invasion or inflammation, the compounds of the 
present invention may be administered orally, topically or 
parenterally. The term parenteral as used includes subcuta-
30 neons injection, intravenous, intramuscular, intrasternal 
injection or infusion techniques. The pharmaceutical com-
positions containing the active ingredient may be in the form 
suitable for oral use, for example as tablets, troches, 
lozenges, aqueous or oily suspension, dispersible powders or 
35 granules, emulsions, hard or soft capsules or syrups or 
elixirs. Dosage levels of the order to 0.2 mg to 140 mg per 
kilogram of body weight per day are useful in the treatment 
of above-indicated conditions (10 mg to 7 gms per patient 
per day). The amount of active ingredient that may be 
40 combined with carrier materials to produce a single dosage 
form will vary depending upon the host treated and the 
particular mode of administration. 
To use the above inhibitors in vitro, they are dissolved in 
an organic solvent such as dimethylsulfoxide or ethanol, and 
45 are added to an aqueous solution containing serine pro-
teases. The final concentration of organic solvent should be 
less than 25%. The inhibitors may also be added as solids or 
in suspension. The serine protease inhibitors of this inven-
tion would be useful in a variety of experimental procedures 
50 where proteolysis is a significant problem. Inclusion of these 
inhibitors in radioimmunoassay experiments would result in 
higher sensitivity. The use of these inhibitors in plasma 
fractionation procedures would result in higher yields of 
valuable plasma proteins and would make purification of the 
55 proteins easier. The inhibitors disclosed here could be used 
in cloning experiments utilizing bacterial cultures, yeast, and 
cell lines. The purified cloned product would be obtained in 
higher yield. 
The following examples are given to illustrate the inven-
60 tion and are not intended to limit it in any manner. 
General Synthesis Procedures 
sis was measured at 410 nm { E410=8800 M-1cm-1; Erlanger 65 
et al., Arch. Biochem. Biophys. 1961, 95, 271-278}. First 
order inactivation rate constants (Kobs) were obtained from 
Benzyl carbamate, triphenyl phosphite, 
4-cyanobenzaldehyde, 1,1'-carbonyldiimidazole (CDI), 1,3-
dicyclohexylcarbodiimide (DCC), and all common chemi-
cals were obtained from the Aldrich Co., Milwaukee, Wis. 
Blocked amino acid derivatives were obtained from Aldrich 
5,952,307 
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or Bachem Bioscience Inc., Philadelphia, Pa. The NMR 
spectra were recorded on a Varian Gemini 300 MHz instru-
ment. 31P NMR spectra were obtained at 161.895 MHz 
using broad band 1H decoupling on a Varian XL-400 instru-
ment; chemical shifts were reported relative to 85% phos- 5 
phoric acid (sealed capillary) at 0.000 ppm with positive 
values downfield. Elemental analyses were performed by 
Atlantic Microlabs of Atlanta, Ga. 
14 
C20H22N3ClP.Y2H20: C,51.85; H, 4.97; N, 9.08; Cl, 15.34. 
Found: C, 51.73; H, 5.02; N, 9.10; Cl, 15.36. 
AlaP(4-F-C6H40)2.HCl, Van4-Me-C6H40)2.HCl, PheP 
(4-Cl-C6H40)2.HC1 can be prepared by the same procedure. 
In general, NH2-CH(R)-P(O)(OZ)(OZ1) hydrochlo-
ride can be prepared from Cbz-NH-CH(R)-P(O)(OZ) 
(OZ1) using the same procedure. This intermediate can then 
be used to prepare a great variety of derivatives by reaction 
with acylating agents, carbamylating agents, sulfonylating 
EXAMPLE 1 
Diphenyl N-benzyloxycarbonylamino( 4-cyanophenyl) 
methanephosphonate { Cbz-( 4-CN-PhGly t( 0 Ph )2} was 
obtained from 9.75 g of 4-cyanobenzaldehyde, 7.65 g of 
benzyl carbamate and 13.5 ml of triphenyl phosphite in 20 
ml of glacial acetic acid, according to the synthetic proce-
dure described earlier (Oleksyszyn J., Subotkowska L., 
Mastalerz P., Synthesis, 1979, 985). Yield 70%; mp. 
135-138° C.; Anal. Calcd. for C28H230 5N2P. Y2H20: C, 
66.27;H, 4.73; N, 5.52. Found: C, 66.03; H, 4.51; N, 5.49. 
10 agents, chloroformates, or by coupling with a variety of 
peptides and blocked peptides using standing peptide cou-
pling reactions, many of which are illustrated in the follow-
ing examples. 
Cbz-NHCH(4-N02-C6H4)PO(OPh)2 and Cbz-NHCH 
(3-Me-C6H4)PO(OPh)2 with m. p. of 151-153° C. and 
127-129° C. respectively were obtained by the same pro-
cedure using the corresponding benzaldehyde. 
Diphenyl N-benzyloxycarbonylamino( 4-amidinopheny 1)-
methanephosphonate hydrochloride { Cbz-( 4-AmPhGlyt 
(0Ph) 2}. A solution of 7 g diphenyl 
N - be n zylo x ye arb on y 1 amino ( 4-cy an op hen yl )-
methanephosphonate in 150 ml of dry chloroform and 15 ml 
of absolute ethanol was saturated with dry HCl at 0° C. The 
mixture was kept in the refrigerator until TLC (thin layer 
chromatography) showed the absence of starting material 
(about 24 hrs). An excess of pentane was added and the 
precipitated solid was removed by filtration and dried using 
a vacuum line. The solid was dissolved in 200 ml of dry 
methanol and gaseous dry ammonia was passed through the 
solution (one equivalentsolution (one equivalent is required) 
for about 20 removed quickly on a rotary evaporator. A 100 
Diphenyl N-(N-benzyloxycarbonylprolyl)amino( 4-
15 amidinophenyl)methanephosphonate hydrochloride (Cbz-
Pro-( 4-AmPhGly)P(OPh)2}. To 0.5 g (2 mmol) of 
N-benzyloxycarbonylproline in 3 ml of dry DMF at 0° C., 
0.45 g (2.77 mmol) of CDI was added and the reaction 
mixture was stirred at 0° C. for 1 hr. Then 0.9 g (2 mmol) 
of diphenyl amino( 4-amidinophenyl)methanephosphonate 
20 hydrochloride was added. After stirring by 18 hrs at 0-5° C., 
10 ml of water was added. The oil which precipitated was 
washed with water and solidified by washing with a cold 0.1 
N solution of HCl. One gram of compound was obtained 
which was used without purification in the next step. 31P 
25 NMR 12.31, 12.62 (free base) and 15.11, 15.41 ppm 
(hydrochloride). After addition of one drop concentrated 
HCl to the NMR tube, 14.22, 14.54 ppm (ratio 1:1). 
30 
35 
Benzoyl-Ala-ValP(OPh)2, Formyl-Ala-ValP(OPh)2, 
Fmoc-Ala-ValP(OPh)2 { Fmoc, 
9-fiuorenylmethyloxycarbonyl}, PhNHCO-Ala-ValP( OPh) 
2, PhNHCS-Ala-ValP(OPh)2, Dansyl-Ala-ValP(OPh)2, 
Tosyl-Ala-van0Ph)2, Trityl-Ala-van0Ph)2, Phthaloyl-
Ala-Valp(OPh)2, Cbz-Pro-AlaP( 4-F-C6H40)2, Cbz-Pro-
Valp( 4-Me-C6H40)2, Cbz-Pro-ValP(3-Cl-C6H40)2, Cbz-
Pro-PheP( 4-Cl-C6H40)2, Cbz-Pro-PheP(4-F-C6H40)2, Cbz-
Ala-ValP (3-Me-C6H4 0)2, Cbz-Ala-PheP(3,4-dichloro-
C6H30)2 can be prepared by the same procedure by 
ml portion of fresh methanol was added and solution was 
heated at 50° C. for about 8 hrs until the TLC shows the 40 
coupling with the appropriate blocked amino acid or amino 
acid derivative. 
absence of imino ether. The solvent was evaporated and the 
resulting oil was dissolved in chloroform. Addition of ether 
caused the oil to solidify. After filtration the resulting solid 
was again dissolved in chloroform, the solution was filtered 
and the solid was precipitated by addition of ether. In several 45 
experiments, the yields were 70--80%; mp. 154--158° C. 
(decamp); 31 P NMR 14.87 ppm. Anal. Calcd. for 
C28H270 5N3ClP.0.3 NH4Cl.H20: C, 57.41; H, 5.16; N, 
7.52; Cl, 7.31. Found: C, 57.75; H, 5.00; N, 8.86; Cl, 7.43 
EXAMPLE 3 
Di phenyl N-(D-Phe-Pro )amino( 4-amidinophenyl)-
methanephosphonate dihydrochloride. One gram of deriva-
tive obtained in the previous experiment was hydrogenated 
in 1 N solution ofHCl in methanol with 0.1g5% Pd/C, until 
the theoretical amount of hydrogen was consumed. After 
filtration of the catalyst and evaporation of the solvent, the 
resulting oil was dried using a vacuum line. A 0.9 g (1.64 
mmol) sample of the product dihydrochloride was added to 
An improved amidination procedure was also developed 
subsequently and should be used in future syntheses. The 
imino ester is dissolved in a freshly prepared solution of 
ammonia (1.5 eq.) in methanol, ammonium chloride (1 eq.) 
is added, and the mixture is then stirred at r. t. for 1 day. 
50 a solution of 0.43 g (1.64 mmol) of Boc-D-Phe and 0.34 g 
(2 mmol) of DCI in 2 ml dry DMF, which was allowed to 
react for 1 hrs at 0° C. After 24 hrs 10 ml of water was added 
and the oil which precipitated was decanted. After washing 
with 0.1 N HCl, the oil which solidified was separated by 
EXAMPLE 2 55 filtration and dried using a vacuum line. The dry solid was 
dissolved in 1 N HCl solution in methanol and solution was 
Diphenyl amino( 4-amidinophenyl)methanephosphonate 
dihydrochloride {(4-AmPhGlyt(OPh)2}. A sample of 1.8 g 
of diphenyl N-benzyloxycarbonylamino( 4-amidinophenyl) 
methanephosphonate hydrochloride was dissolved in 150 ml 60 
of 2N HCl methanol solution and after addition of 5% Pd/C 
catalyst, the solution was stirred under an atmosphere of 
hydrogen until the theoretical amount of hydrogen was 
consumed. The catalyst was removed by filtration and after 
evaporation of the methanol, the residue was crystallized 65 
from ethanol-ether. In several experiments, the yields were 
60-80%; mp. 213-215° C.; Anal. Calcd. for 
stirred by 1 hr. Solvent was removed on a rotary evaporator 
and the oil was dried using a vacuum line by several hours 
to give 0.3 g of product. Yield 24%; mp. 220-224° C.; 31P 
NMR, 16.95, 17.25, 17,60 ppm (stereoisomers and 
conformers). Anal. Calcd. for C34H380 5N2ClP.5H20: C, 
51.78; H, 6.09; N, 8.88; Cl, 9.00; Found; C, 51.21; H, 5.95; 
N, 9.04; Cl, 8.97. 
EXAMPLE 4 
Diphenyl N-(Boc-D-Phe-Pro )amino( 4-amidinophenyl)-
methanephosphonate hydrochloride {Boc-D-Phe-L-Pro-( 4-
5,952,307 
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AmPhGlyt(OPh)2}. Boc-D-Phe-OH (2.66 g, 10 mmole) 
and L-Pro-OBzl (2.42 g) were coupled using DCC, and 
Boc-D-Phe-Pro-OBzl was obtained in 83% yield; 1H NMR 
(CDC13) ll 7.34 (s, SH), 7.23 (m, SH), S.4 (d, lH), S.lS (q, 
2H), 4.6S (m, lH), 4.3S (m, lH), 3.5 (m, lH), 3.1-2.9 (m, 5 
2H), 2.6 (m, lH), 2.-1.7 (m, 4H), 1.43 (s, 9H). 
C26H23N20 4P: C, 68.12; H, S.02; N, 6.11. Found: C, 66.87; 
H, S.lS; N, S.01. 
EXAMPLE 7 
4-Cyanophenylacetaldehyde. This compound was pre-
pared from 4-cyanobenzaldehyde using a modification of a 
procedure previously used in the multi-step synthesis of 
2-phenylpropanal {Allen, C. F. H.; van Allan, J., Org. Syn. 
Coll. Vol 3, 733-734 (19SS)}. 
Hydrogenolysis was performed in methanol with S% 
water using S% Pd/Casa catalyst. The product Boc-D-Phe-
Pro-OH was obtained as a white solid and recrystallized 
from aqueous methanol, yield 8S%, mp 173-174° C.; 1H 
NMR (DMSO) ll 7.3-7.lS (m, SH), 7.0 (d, lH), 4.4S(m, 
lH), 4.10 (m, lH), 3.6-2.7 (m, 4H), 2.2-1.6 (m, 4H), 1.30 
(s, 9H); MS (FAE+) m/e 363 (M+l); {a}20D=-91.5° (0.14 
g/mL in methanol). Anal. (C19H26N20 5) C, H, N. 
To 0.36 g (1.0 mmol) of Boc-D-Phe-Pro-OH in 2 ml of 
dry DMF at 0° C., 0.17 g (1.0S mmol) of CDI was added. 
After stirring for 1 hr at 0° C., OAS g (1.0 mmol) of 
dihydrochloride of diphenyl amino( 4-amidinophenyl) 
methanephosphonate was added and the solution was stirred 
for 48 hrs at 0° C. Water (10 ml) was added and the oil which 
precipitated out was decanted and washed with distilled 
water. The oil was dissolved in chloroform and the solution 
was washed with 4% NaHC03, water, and O.OS N HCl. After 
drying over MgS04, the solvent was removed and the 
resulting oil was dried on a vacuum line for a few hours to 
give 0.22 g of product. Yield 29%; mp. 18S-190° C.; 31P 
NMR, 12.42, 12.66, 12.79 ppm (stereoisomers and 
conformers) (free base); lS.12, lS.38, 1S.S8 
(hydrochloride). Anal. Calcd. for C39H45Q7 N5ClP.l/2H20: 
C, 60.7S; H, S.97; N, 9.08; Cl, 4.60. Found: C, 60.98; H, 
6.48; N, 8.26; Cl., 4.26. 
Tosyl-D-Phe-Pro-ArgP(OPh)2, Cbz-D-Phe-Pro-ArgP 
(0Ph)2, Boc-D-Phe-Pro-Ar~(OPh)2, Boc-D-Phe-Pro-OmP 
(0Ph)2, Boc-D-Phe-Pro-Ar~( 4-F-C6H40)2, Boc-D-Phe-
Pro-Argp( 4-Me-C6H4 0)2, Boc-D-Phe-Pro-ArgP(3,4-
dichloro-C6H30)2 Boc-D-Phe-Pro-Ar~(3-Cl-C6H40)2 can 
be prepared by the same procedure by coupling with the 
appropriate blocked peptide or peptide derivative. 
EXAMPLES 
Diphenyl N-(N-~-naphylsulfonylglycyl)amino( 4-
amidino-phenyl)methanephosphonate hydrochloride 
{2-NpS02-Gly-(4-AmPhGlyt(OPh)2}. Using the same 
procedure as example S, 0.3 g (1.13 mmol) of 
~-naphylsulfonylglycine, 0.2 g (1.23 mmol) of CDI and 0.4S 
g (1.0 mmol) of diphenyl amino( 4-amidinophenyl) 
methanephosphonate dihydrochloride (obtained in Example 
3) were reacted and 0.21 g of product was obtained. Yield 
30%; mp. 20S-210° C. (decamp); 31P NMR, 11.76 ppm 
(free base), 14.74 ppm (hydrochloride). Anal. Calcd. for 
C32H300 6N4ClPS.H20: C, S6.24; H, 4.69; N, 8.20; S, 4.69. 
Found: C, S6.87; H, 4.43; N, 8.79; S, S.06. 
EXAMPLE 6 
Benzoyl-NHCH( 4-NH2-C6H4)PO(OPh)2. NH2CH( 4-
N02-C6H4)PO(OPh)2.HBr was obtained by deblocking 
Cbz-NHCH(4-N02-C6H4)PO(OPh)2 with 30% of HBr/ 
HOAc, mp. 198-200° C. The reaction of NH2CH( 4-N02-
C6H4)PO(OPh)2.HBr and benzoyl chloride in the presence 
of N-methylmorpholine gave benzoyl-NHCH(4-N02-
C6H4)PO(OPh)2, mp. 1S7-1S9° C., mass spectrum m/e=489 
(M+ +1).Anal. Cale. for C26H21N20 6P: C, 63.88; H, 4.30; N, 
S.73. Found: C, 64.0S; H, 4.2S; N, S.69. Hydrogenolysis of 
benzoyl-NHCH(4-N02-C6H4)PO(OPh)2 in the presence 
of Pd/C catalyst gave the final product, mp. 1S6-1S8° C., 
mass spectrum m/e=4S8 (M+). Anal. Cale. for 
10 
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Ethyl 3-( 4-cyanophenyl)-2,3-epoxypropionate. Ethyl 
chloroacetate ( 6.2 g, SO mmole) and 4-cyanobenzaldehyde 
(6.6 g, SO mmole) were dissolved in 100 mL dry benzene. 
Freshly prepared sodium ethoxide solution in absolute etha-
nol (1.3 g sodium in 2S mL ethanol) was added and the 
mixture was stirred at r.t. for 20 h. Water (100 mL) was 
added with stirring and after several minutes the organic 
layer was separated, washed with water, dried (MgS04), 
filtered, and evaporated to give the desired epoxy product as 
a yellow oil, yield 70-80%; 1H NMR (CDC13) ll 7.68 (d, 
2H), 7.43 (d, 2H), 4.30 (m, 2H), 4.16 (d, lH), 3.48, (d, lH), 
1.34 (t, 3H). 
Sodium 3-( 4-cyanophenyl)-2,3-epoxypropionate. Ethyl 
3-( 4-cyanophenyl)-2,3-epoxypropionate (10.9 g, SO mmole) 
25 was dissolved in SO mL absolute ethanol and cooled with an 
ice bath. A freshly prepared sodium ethoxide solution (1.2 g 
sodium in 2S mL ethanol) was added dropwise during a 10 
min period. Dropwise addition of 1 g of water to the stirred 
mixture caused separation of the sodium salt of the epoxy 
30 compound. The mixture was stirred for 3 h, the salt was 
collected by filtration, washed with SO mL ethanol and ether 
several times, and dried, yield 7S-8S%; 1H NMR (D20) ll 
7.58 (d, 2H), 7.33 (d, 2H), 3.93 (d, lH), 3.39 (d, lH). 
A lN HCl solution (SO mL, SO mmole) was added to the 
35 sodium salt of the epoxy compound (10.6 g, SO mmole) 
dissolved in SO mL water. This resulted in the separation of 
an oil which solidifed after a short time. This material was 
refluxed with 100 mL toluene for 2.5 h to affect decarboxy-
lation. The organic layer was separated, washed with water, 
40 dried (Na2S04), filtered, and evaporated to give 
4-cyanophenylacetaldehyde as a yellow brownish oil which 
solidified after several hours, yield 3S-4S%. This product is 
unstable and was used immediately for next step, otherwise 
polymerization occurs. A sample of the crude product was 
45 purified by recrystallization from ether-hexane to give white 
crystals, mp 63-6S 0 C.; NMR (CDC13) ll 9.81 (s, lH), 7.6S, 
(d, 2H), 7.3S (d, 2H), 3.84 (s, 2H); MS m/e 146 (M+l).Anal. 
(C9H7 N0.0.5H20) C, H, N. 
Di phenyl 1-(N-Benzyloxycarbonylamino )-2-( 4-
50 cyanophenyl)ethanephosphonate { Cbz-( 4-CN-Phe t(OPh) 
2}. This compound was synthesized from crude 
4-cyanophenylacetaldehyde, benzyl carbamate, and triph-
enylphosphite using a modification of the previously 
described amidoalkylation procedure.9 Benzyl carbamate 
55 (6.1g,40 mmole) and 4-cyanophenylacetaldehyde ( 4.7 g, 32 
mmole) were dissolved in SO mL toluene and refluxed for 1 
h. The toluene was evaporated, glacial acetic acid (10 mL) 
and triphenyl phosphite (8.5 mL, 32 mmole) were added to 
the residue, and the mixture was heated at 80° C. for 2 h. The 
60 volatile materials were removed by evaporation in vacuo 
and the resulting oil was dissolved in SO mL methanol. The 
solution was refrigerated overnight and the white precipitate 
was filtered, dried, and recrystallized from SO mL hot 
methanol. The undissolved product was discarded, and the 
65 filtrate was cooled down to give white crystals, yield 
2S-3S%; mp 136-137° C.; 1H NMR (DMSO) ll 8.20 (d, 
lH), 7.7S (d, 2H), 7.54 (d, 2H), 7.3S (m, SH), 7.3-7.1 (m, 
5,952,307 
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lOH), 4.95 (q, 2H), 4.60 (m, lH), 3.4-3.0 (m, 2H); MS 
(FAE+) m/e 513 (M+l). Anal. (C29H25N20 5P) C, H, N. 
Diphenyl l-Amino-2-( 4-cyanophenyl)ethanephosphonate 
Hydrobromide {4-CN-PheP(OPh)2.HBr}. Cbz-(4-CNPhet 
(0Ph)2 (0.57 g, 1.1 mmole) was mixed with 1.0 mL 30% 5 
HBr in acetic acid. The mixture was protected against 
moisture and kept at r.t. for 1 h. Addition of 50 mL dry ether 
and stirring for several hours resulted in formation of a 
yellow brownish solid which was filtered, washed with 
ether, and dried to give the product (0.48 g, 95%); mp 10 
197-199° C.; 1H NMR (DMSO) ll 9.0 (b, 3H), 7.85 (d, 2H), 
7.65 (d, 2H), 7.4-7.0 (m, lOH), 4.7 (m, 1H), 3.4 (m, 2H); MS 
(FAE+) m/e 379 (M-Br). 
18 
lH), 7.8-7.2(m, 19H), 5.06 (m, 2H), 4.95 (m, lH), 4.6 (q, 
lH), 4.2 (m, lH), 3.5-3.1 (m, 3H), 2.0--1.4 (m, 4H); MS 
(FAE+) m/e 610 (M+l). Anal. (C34H32N30 6P) C, H, N. 
EXAMPLE 10 
Diethyl l-(N-benzyloxycarbonyl-L-prolyl)amino-2-( 4-
amidinophenyl)ethanephosphonate { Cbz-Pro-( 4-AmPhe t 
(0Et)2, 10}. This compound was obtained during the amidi-
nation procedure of dipeptide Cbz-Pro-(4-CN-Phet(OPh)2 
when ethanol was used instead of methanol. Transesterifi-
cation occurred and the phenyl groups were replaced by 
ethyl groups, yield 50% (0.11 g); mp >130° C. (dee); 1H 
NMR (DMSO) ll 9.4-9.2 (m, 4H), 8.4 (m, lH), 7.8-7.1 (m, 
9H), 5.0 (s, 2H), 4.5 (m, lH), 4.2 (m, lH), 4.0 (m, 4H), 
15 3.5-2.9 (m, 4H), 2.1-1.4 (m, 4H), 1.25 (m, 6H); MS (FAE+) 
m/e 531 M-Cl). Anal. (C26H36N40 6ClP) C, H, N. 
Diphenyl 1-(N-Benzyloxycarbonylamino )-2-( 4-
amidinophenyl)ethanephosphonate { Cbz-( 4-AmPhe )P 
(0Ph)2}. Cbz-(4-CNPhet(OPh)2 (1.03 g, 2.0 mmole) was 
dissolved in a mixture of methanol and chloroform (1:1, 20 
mL). The solution was cooled to 0° C., saturated with dry 
HCl, the solution was kept at 5° C. for 48 h, and then the 
solvent was evaporated at r.t. in vacuo. The resulting semi- 20 
solid was treated with 50 mL dry ether, filtered, washed with 
dry ether, and dissolved in 10 mL methanol containing 51 
mg (3.0 mmole) ammonia. Ammonium chloride (107 mg, 
2.0 mmole) was added, the mixture was stirred at r.t. for 1 
day, the solvent was removed at r.t. in vacuo and the 25 
resulting semisolid was dissolved in 50 mL chloroform, 
filtered, and the filtrate was evaporated to give the crude 
product. The crude product was treated with 50 mL dry 
ether, stirred, and the undissolved solid collected, washed 
with ether and dried to give the amidine product as a yellow 30 
powder, yield 50-70%; mp >140 (dee); 1H NMR (DMSO) 
ll 9.4-9.2 (d, 4H), 8.25 (d, lH), 7.8 (d, 2H), 7.6 (d, 2H), 7.38 
(m, SH), 7.3-7.1 (m, lOH), 4.95 (q, 2H), 4.6 (m, lH), 
3.4-3.1 (m, 2H); MS (FAE+) m/e 530 M-Cl). Anal. 
(C29H29N30 5ClP) C, H, N. 35 
EXAMPLE 8 
Diphenyl l-Amino-2-( 4-amidinophenyl) 
EXAMPLE 11 
Diphenyl 1-(N-t-Butyloxycarbonyl-D-pheny lalany l-L-
prolyl)amino-2-( 4-cyanophenyl)ethanephosphonate {Boc-
D-Phe-Pro-( 4-CN-Phe t(OPh)2}. The phosphonate 4-CN-
PheP(OPh)2.HBr (0.46 g, 1 mmole) was coupled with Boc-
D-Phe-Pro-OH (0.36 g, 1.0 mmole) using DCC. The product 
was obtained as a glass-like solid, yield 86% (0.62 g); mp 
85-90° C.; 1H NMR (DMSO) ll 8.25 (2d, lH), 7.8-7.0 (m, 
19H), 4.8 (m, lH), 4.4 (m, lH), 4.3 (m, lH), 4.2 (m, lH), 
3.5-2.8 (m, 4H), 2.0-1.4 (m, 4H), 1.3 (m, 9H); MS (FAE+) 
m/e 723 (M+l). Anal. (C40H43N40 7 P.0.25 H20) C, H, N. 
EXAMPLE 12 
Diphenyl 1-{ (N-t-Butyloxycarbonyl-D-phenylalanyl-L-
proly l)amino }-2-( 4-amidinophenyl)ethanephosphonate 
{Boc-D-Phe-Pro-(4-AmPhet{OPh)2}. CDI (0.13 g, 0.8 
mmole) was added to Boc-D-Phe-Pro-OH (0.24 g, 0.67 
mmole) in 2 mL DMF. A solution of amidine (4-AmPhet 
(0Ph)2.2HC1 (0.31 g, 0.67 mmole) in 2 mL DMF was added 
to a cooled solution (0° C.) of the peptide and the mixture 
was incubated at 0° C. for 2 h and r.t. for 48 h. DMF was 
40 removed in vacuo and the residue oil was dissolved in 100 ethanephosphonate {(4-AmPhet(OPh)2.2HCl}. The ami-
dine Cbz-(4-AmPhet(OPh)2 (1.0 g, 1.76 mmole) was dis-
solved in 150 mL methanol containing 2 mmole HCl, a 
catalyst (0.5 g of 5% Pd/C) was added, and the mixture was 
hydrogenated. After hydrogenolysis, the catalyst was 
removed by filtration and the filtrate was evaporated to give 45 
a near white crystalline product, yield 85-90%; mp > 180 
(dee.); 1H NMR (DMSO) ll 9.5-9.3 (d, 4H), 9.2-9.0 (m, 
3H), 7.9-7.1(m,14H), 4.55 (m, lH), 3.2-3.5 (m, 2H); MS 
(FAE+) m/e 396 (M+l-2HC1). Anal. (C21H24N3Q3Cl2P) C, 
H,N. 
EXAMPLE 9 
Diphenyl 1-(N-Benzyloxycarbonyl-L-prolyl)amino-2-( 4-
cyanophenyl)ethanephosphonate { Cbz-Pro-( 4-CN-Phe t 
(0Ph)2}. To a cooled solution of the phosphonate 4-CN-
PheP(OPh)2.HBr (0.41 g, 0.9 mmole) and Cbz-Pro-OH 
(0.25 g, 1.0 mmole) in 20 mL CH2Cl2 was added 0.14 mL 
triethyl amine. After stirring for 10 min, DCC (0.21 g, 1.0 
mmole) was added and the mixture was stirred at 0° C. for 
50 
mL CHC13, filtered, and the organic layer was washed 
subsequently with 50 mL 0.05 M HCl, 10% KCl, 6% 
NaHC03, and water. The organic layer was dried, filtered, 
and evaporated to give a crystalline product which was then 
dried in vacuo, yield 59% (0.31 g); mp 145-155° C. (dee.); 
1H NMR (DMSO) ll 10.1-9.7 (m, 2H), 9.4-9.0 (m, 3H), 
8.0-7.0 (m, 19H), 6.75 (m, lH), 4.9-4.0 (m, 3H), 3.5-2.6 
(m, 6H), 2.0-1.4 (m, 4H), 1.3 (s, 9H); MS (FAE+) m/e 740 
M-Cl). Anal. (C40H46N50 7 P.0.3HC1.1.5H20) C, H, N. 
EXAMPLE 13 
Diphenyl l-(N-(D-Phenylalanyl-L-prolyl)amino-2-( 4-
amidinopheny l)ethanephosphonate Dihydrochloride 
{D-Phe-Pro-( 4-AmPhe )P(OPh)2}. Boc-D-Phe-Pro-( 4-
55 AmPhet(OPh)2 (0.11 g) was dissolved in 2 mL CHC13 and 
the solution was saturated with dry HCl. An oily precipitate 
formed and the mixture was kept at r.t. for 2 h before 
evaporating to dryness to obtain the crystalline product, 
yield 80% (0.08 g); mp >165° C. (dee); 1H NMR (DMSO) 
60 ll 9.4-9.2 (d, 4H), 8.5 (m, 3H), 8.2 (m, lH), 7.9-7.0(m, 
19H), 4.8-3.9 (m, 3H), 3.5-2.8 (m, 6H), 2.0-1.1 (m, 4H); 
MS (FAE+) m/e 640 (M+l-2Cl). Exact mass calcd. for 
C35H39N50 5P (M+l-2HC1) 640.2689. Found: 640.2786. 
2 hand at r.t. for 24 h. During this period, dicyclohexylurea 
(DCU) formed, was removed by filtration and the filtrate 
was evaporated. The residue was dissolved in 50 mL ethyl 
acetate, filtered, the filtrate was washed with 50 mL lN HCl, 
water, 6% NaHC03, and water. The organic layer was dried, 
filtered, and evaporated to give crude product which was 65 
then recrystallized from ether to give white crystals, yield 
52% (0.29 g); mp 131-132° C.; 1H NMR (DMSO) ll 8.75(m, 
EXAMPLE 14 
Boc-Phe-Phe-(4-AmPhGlyt(OPh)2. To a THF solution 
(5 ml) of Boc-Phe-Phe-OH (0.21 g, 0.5 mmol) was added 
5,952,307 
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successively N-methylmorpholine (55 µl, 0.5 mmol) and 
isobutyl chloroformate (65 µl, 0.5 mmol) at -15° C. After 
stirring for 2 min and addition of cold THF solution (1 ml) 
of triethylamine (70 µl, 0.5 mmol), the mixture was added to 
a DMF solution (1 ml) of (4-AmPhGlyt(OPh)2. 2HC1 (0.23 5 
g, 0.5 mmol) at -15° C. After stirring at -15° C. for 1 hr and 
at 0-5° C. for 12 hr, the reaction mixture was concentrated 
in vacuo. The residue was triturated with ether and was 
purified by chromatography (silica gel, CHC13/CH30H, 
14:1) and solidified from ether to give the final product (SO 10 
mg, 20% yield) as a white powder; mp 149-170° C., R_r0.45 
(CHC13/CH30H/CH3C02H, S0:10:5), Anal. Calcd. for 
C43H47Q7N5Cl.H20: C, 62.2; H, 5.95; N, S.43. Found: C, 
20 
the product as white solid: mp 123-126° C.; yield 75%; 1H 
NMR (DMSO) ll 1.4-2.0 (m, 6H), 2.7-2.S (m, 2H), 4.2-4.4 
(m, lH), 5.0--5.2 (m, 2H), 7.1-7.4 (m, 15H), 7.S-S.1 (m, 
3H); MS (FAE+) m/z calcd for C15H290 5N2P (M+l) 469.3. 
Anal. (C25H290 5N2P.HC1.0.7H20) C, H, N. 
EXAMPLE 16 
4-Phthalimidobutanol. This compound, a colorless oil, 
was prepared in the same manner as 5-phthalimidopentanol: 
yield 100%; 1H NMR (CDC13) ll 1.6-1.7 (m, 2H), 1.7-1.9 
(m, 2H), 3.7 (t, 1=7.7 Hz, 2H), 4.35 (t, 1=6.4 Hz, lH), 
7.7-7.S (m, 2H), 7.S-7.9 (m, 2H), 7.S-7.9 (m, 2H). 
4-Phthalimidobutanal. This compound, a colorless oil, 62.3; H, 6.01; N, S.45. 
EXAMPLE 15 
15 was prepared in the same manner as 5-phthalimidopentanal; 
yield 3S%; 1H NMR (CDC13) ll 2.0-2.1(m,2H), 2.5-2.6 (td, 
1=6.0, 1.1, 2H), 3.7-3.S (t, 1=6.S Hz, 2H), 7.7-7.S (m, 2H), 
7.S-7.9 (m, 2H), 9.S (s, lH); MS (EI+l m!z 217.1. 5-Phthalimidopentanol. A mixture of phthalic anhydride 
(6.46 g, 43.6 mmol) and 5-aminopentanol (4.5 g, 43.6 
mmol) was heated to 145° C. in an open flask for 30 min. A 
stream of N2 was applied to expel water vapor. After cooled 
20 
to room temperature, the reaction residue was dried on 
vacuum pump. The product was obtained as colorless oil: 
yield 100%; 1H NMR (CDC13) ll 1.4-1.5 (m, 2H), 1.6-1.S 
(m, 4H), 3.6 (t, 2H, 1=6.5), 3.7 (t, 1=7.2 Hz), 7.7 (m, 2H), 
D iphenyl N -(N -Benzyloxycarbonyl)amino(3-
phthalimidopropyl)methanephosphonate { Cbz-Orn(Phtt 
(0Ph)2}. This compound was prepared in the same manner 
as Cbz-Lys(Phtt(OPh)2: mp 72-74° C.; yield 47%; 1H 
NMR (CDC13) ll 1.5-2.2 (m, 4H), 3.S (t, 1=6.S Hz, 2H), 
4.5-4.7 (m lH), 5.0-5.2 (m, 2H), 7.0-7.4 (m, 15H), 7.7 (m, 
7.S-7.9 (m, 2H). 25 2H), 7.9 (m, 2H); MS (FAE+) m/z 5S5.0. 
D iphenyl N -(N -Benzyloxycarbonyl)amino(3-
aminopropyl)methanephosphonate { Cbz-OrnP(OPh)2}. 
This compound was prepared in the same manner as Cbz-
LysP(OPh)2 with exception that the product was obtained as 
30 an acetate salt: 111-113° C.; yield 66%; 1H NMR (DMSO) 
ll 1.S (s, 3H), 1.5-2.1 (m, 4H), 2.6-2.7 (m, 2H), 4.2-4.4 (m, 
lH), 5.0-5.2 (m, 2H), 7.1-7.5 (m, 15H), S.1 (br s, lH); MS 
(FAE+) m/z 455.0. Anal (C24H270 5N2P.C2H40 2) C, H, N. 
5-Phthalimidopentanal. The preparation of this compound 
begins by adding oxaly chloride ( 4.6 mL, 53.2 mmol) to 60 
mL of freshly distilled CH2Cl2 containing DMSO (6.9 mL, 
96.0 mmol) at -45° C., and stirring for 5 min. The dropwise 
addition (over 20 min) of phthalic alcohol (10.2 g, 43.6 
mmol) in 40 mL CH2Cl2 was followed by an additional 15 
min stirring, and then DIEA (22.S mL, 130.9 mmol) was 
introduced. At this time the reaction temperature was 
warmed to -30° C. and stirring continued for 30 min. The 35 
solvent was removed and the residue was taken-up in 100 
mL EtOAc, filtered to remove any DIEA salt, washed with 
6% NaHC03 and water (3x40 mL), and dried over Na2S04. 
After filtering the solvent was removed yielding the 
aldehyde, a yellow oil: yield SS%; 1H NMR (CDC13) ll 40 
1.6-1.9 (m, 4H), 2.5 (t, 1=6.3 Hz, 2H), 3.7 (t, 1=7.S, 2H), 
7.6-7.9 (m, 4H), 9.7 (s, lH); MS (EI+) m/z 231.1. 
EXAMPLE 17 
6-Phthalimidohexanol. This compound was prepared in 
the same manner as 5-phthalimidohexanol from 
6-aminohexanol (3.51 g, 30.0 mmol) and phthalic anhydride 
(4.44 g, 30.0 mmol) to give the product as brown oil: yield 
91%; 1H NMR (CDC13) ll 1.3-1.S (m, SH), 3.6-3.7 (m, 4H), 
4.3 (t, 1=6.5 Hz, lH), 7.7 (m, 2H), 7.S (m, 2H). 
6-Phthalimidohexanal. This compound was prepared in 
the same manner as 5-phthalimidopentanal from 
Diphenyl N-(N-Benzyloxycarbonyl)amino( 4-
phthalimidobutyl)methanephosphonate { Cbz-Lys(Phtt 
(0Ph)2)}. To a mixture of 5-phthalimidopentanal (S.9 g, 
3S.5 mmol), triphenylphosphite (10.1 mL, 3S.5 mmol) and 
benzyl carbamate (5.S g, 3S.5 mmol) was added 100 mL 
acetic acid. The solution was stirred at S0--90° C. for one 
hour. Acetic acid was removed in vacuo. Crystallizing from 
methanol yielded the phosphonate product as a white solid: 
mp 100--102° C.; yield 29.1%; 1H NMR (CDC13) ll 1.5-2.2 
(m, 6H), 3.7 (t, 2H, 1=6.3 Hz,), 4.4--4.6 (m, lH), 5.0-5.3 (m, 
2H), 7.0--7.4 (m, 15H), 7.7 (m, 2H), 7.9 (m, 2H). Anal. 
(C33H31 0 7N2P) C, H, N. The analytical data are consistent 
with reported data.32 
Diphenyl N-(N-Benzyloxycarbonyl)amino( 4-
aminobutyl)methanephosphonate Hydrochloride { Cbz-LysP 
(0Ph)2}. Cbz-Lys(Phtt(OPh)2 (0.6 g, 1.0 mmol) was dis-
solved in hot i-PrOH (60° C.) followed by addition of 
hydrazine (0.1 mL, 3.0 mmol) via a syringe. The reaction 
mixture was allowed to stir for three hours at 60° C. The 
solid formed was filtered and the solvent was removed. The 
remaining residue was taken up in 100 mL of CHC13, and 
washed with saturated NaCl (4x60 mL) and then dried over 
Na2S04. After the CHC13 solution was cooled to 0° C. the 
solution was saturated with gaseous HCl. Finally, the solvent 
was removed and the residue was triturated in ether to give 
45 6-phthalimidohexanol (6.73 g, 27.2 mmol), DMSO ( 4.3 mL, 
59.S mmol), oxalyl chloride (2.9 mL, 32.7 mmol) and DIEA 
(14.2 mL, Sl.7 mmol) to give the product as light brown oil: 
yield Sl %; 1H NMR (CDC13) o 1.4 (m, 2H) 1.7 (m, 4H), 2.5 
(td, 1=7.1, 1.2 Hz, 2H), 3.7 (t, 1=6.3 Hz, 2H), 7.7-7.9 (m, 
50 4H), 9.S (s, lH). 
D iphenyl N -(N -Benzyloxycarbonyl)amino( 6-
phthalimidohexyl)methanephosphonate { Cbz-HomoLys 
(Phtt(OPh)2}. This compound was prepared in same man-
ner as Cbz-Lys(Phtt(OPh)2 from 6-phthalimidohexanal 
55 (5.3S g, 22.0 mmol), triphenylphosphite (5.75 g, 22.0 mmol) 
and benzyl carbamate (3.33 g, 22.0 mmol) to give the 
product as a light brown solid: mp 95-96° C.; yield 40%; 1H 
NMR (CDC13) ll 1.3-2.1 (m, SH), 3.7 (t, 1=6.6 Hz. 2H), 
4.4-4.5 (m, lH), 5.1-5.2 (m, 2H), 7.0-7.4 (m, 15H), 7.7 (m, 
60 2H), 7.9 (m, 2H). Anal (C34H330 7N2P) C, H, N. 
D iphenyl N -(N -Benzyloxycarbonyl)amino( 6-
aminohexyl)methanephosphonate { Cbz-HomoLysP 
(0Ph)2}. This compound was prepared in same manner as 
Cbz-LysP(OPh)2, mp 69-71° C.; yield 59%; 1H NMR 
65 (CDC13) ll 1.2-2.0 (m, SH), 2.7-2.9 (br s, 2H), 4.4 (m, lH), 
5.0 (m, 2H), 6.0 (d, 1=9.6 Hz, lH), 7.0-7.3 (m, 15H), 
S.0-8.2 (br s, 3H); MS (FAE+) m/z 4S3.1. 
21 
EXAMPLE 18 
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Diphenyl N-(trans-Cinnamoyl)amino( 4-amidinophenyl) 
methanephosphonate Hydrochloride { trans-Cinnamoyl-( 4-
AmPhGlyt(OPh)J; mp 111-118° C.; yield, 18%; 1H NMR 5 (DMSO) ll S.2-S.4 (m, lH), 6.1-6.4 (m, lH), 6.6-6.8 (m, 
2H), 6.9-7.6S (m, 16H), 7.6S-8.0 (m, 3H), 8.4-8.6 (m, lH), 
8.7-8.9 (m, lH), 9.1-9.7 (m, 3H); MS (FAE+) m/z S12.2. 
Anal. (C29H260 4N3P.HC1.H20) C, H, N. 
22 
Phenoxybenzoyl)-Pro-(4-AmPhGlyt{OPh)2}. Mp 90-9S 0 
C.; yield, 43%; 1H NMR (DMSO) ll 1.SS-1.9 (m, 3H), 
2.0S-2.3(m, lH), 3.2-3.6 (m, 2H), 4.5-4.7 (m, lH), 
S.8-6.lS (m, lH), 6.7-7.6 (m, 19H), 7.7-7.9 (m, 4H), 
9.lS-9.S (m, 4H); HRMS (FAW) m/z calcd for 
C38H350 6N4P (M+l) 67S.2372, found 67S.2338. Anal. 
(C38H350 6N4P.HC1.0.5DMF) C, H, N. 
EXAMPLE 2S 
EXAMPLE 19 
Dip hen yl N -( 3-( 2-Furyl) acrylo yl) amino ( 4-
amidinophenyl)methanephosphonate Hydrochloride { 3-(2-
Furyl)acryloyl-( 4-AmPhGlyt(OPh)2, 17}; mp 97-10S 0 C.; 
yield, 10%; 1H NMR (DMSO) ll 6.1-6.3 (dd, 1H, 1=9.8 Hz), 
6.SS-6.63 (m, lH), 6.7-6.8 (m, 2H), 6.83-6.84 (d, lH, 1=3.3 
Hz), 7.0-7.1 (m, 4H), 7.1-7.2S (m, 3H), 7.3-7.4 (m, 4H), 
7.4S-7.6S (m, lH), 7.8-7.9S (m, 4H), 9.2-9.4 (m, 3H), 
9.6-9.6S (m, lH); MS (FAW) m/z S02.4. Anal. 
(C27H240 5N3P.HC1) C, H, N. 
EXAMPLE 20 
Diphenyl N-(3-(2-Thienyl)acryloyl)amino( 4-
amidinophenyl)methanephosphonate Hydrochloride { 3-(2-
Thienyl)acryloyl-( 4-AmPhGlyt(OPh)2, 18 }; mp 114-119° 
C.; yield, 17%; 1H NMR (DMSO) ll 6.1S-6.2S (dd, 1H, 
1=9.0 Hz), 6.6S-6.8S (m, 2H), 7.0-7.lS (m, SH), 7.1S-7.2S 
(m, 2H), 7.3-7.4S (m, SH), 7.6-7.71 (m, 2H), 7.8-7.9 (m, 
4H), 9.5-9.6 (m, lH), 9.6S-10.1 (br s, 3H); MS (FAE+) m/z 
S18.0. Anal. (C27H240 4N3SP.0.5HC.H20) C, H, N. 
EXAMPLE 21 
Dipheny 1 N-( trans-3-(3-Pyridy l)acry loyl)amino( 4-
amidinophenyl)methanephosphonate Hydrochloride {trans-
3-(3-Pyrid y l )acry loy l-( 4-AmPhGly)P(OPh)2}; mp 
103-109° C.; yield, 17%; 1 H NMR (DMSO) ll 6.lS-6.3 (m, 
lH), 6.7-6.8 (d, lH), 6.9-7.6 (m, 14H), 7.7-8.1 (m, SH), 
8.5-8.6 (m, lH), 8.7-8.9 (m, lH), 9.1-9.7 (br s, 2H), 
9.9-10.0 (m, lH); HRMS (FAE+) m/z calcd. for 
C28H250 4N4P (M+l) S13.1692, found S13.1730. Reversed 
phase HPLC (90% MeCN-H20), tR=2.5l min. 
EXAMPLE 22 
Dip hen yl N -(3-Phe noxybe nzo yl) amino ( 4-
amidinophenyl)methanephosphonate Hydrochloride 
{3-Phenoxybenzoyl-(4-AmPhGlyt(OPh)2}; mp SS-93° C.; 
yield, 32%; 1H NMR (DMSO) ll 6.2-6.4 (m, lH), 7.0-7.3 
(m, lOH), 7.3-7.5 (m, SH), 7.6-7.7 (m, 2H), 7.8-8.0 (m, 
4H), 9.2-10 (m, 4H); HRMS (FAE+) m/z (M+Cl) calcd. for 
C33H28 0 5N3P S78.184S, found S78.1828. Anal. 
(C33H280 5N3P.HC1.0.7SDMF) C, H, N. 
EXAMPLE 23 
Diphenyl N-(2-Phenoxybenzoyl)amino( 4-
amidinophenyl)methanephosphonate Hydrochloride 
{2-Phenoxybenzoyl-(4-A mPhGlyt(OPh)2}; mp SS-93° 
C.; yield, 28%; 1H NMR (DMSO) ll 6.1-6.3 (m, lH), 
6.9-7.1 (m, SH), 7.1-7.26 (m, 3H), 7.26-7.4 (m, 7H), 
7.4S-7.6 (m, 3H), 7.7S-7.9 (m, 6H), 9.5-10.5 (m, 4H); MS 
(FAE+) m/z S78.0. Anal. (C33H280 5N3P.HC1.1.5H20) C, H, 
N. 
EXAMPLE 24 
Diphenyl N-(N-(2-Phenoxybenzoylprolyl))amino( 4-
amidinophenyl)methanephosphonate Hydrochloride { (2-
10 Diphenyl N-(N-(3-Phenoxybenzoylprolyl))amino( 4-
amidinophenyl)methanephosphonate Hydrochloride { (3-
Phenoxybenzoy l)-Pro-( 4-AmPhGly)P( 0Ph) 2}. Mp 
104-110° C.; yield, 33%; 1H NMR (DMSO) ll 1.S-1.9 (m, 
3H), 2.1-2.3 (m, lH), 3.2-3.6 (m, 2H), 4.5-4.8 (m, lH), 
15 S.9-6.2 (m, lH), 6.7-6.9 (m, lH), 6.9-7.3 (m, llH), 7.3-7.5 
(m, 7H), 7.7-7.9 (m, 4H), 9.1-9.4 (m, lH), 9.4-9.6 (m, lH), 
9.6-10.0 (br s, 2H); MS (FAE+) m/z 67S.1. Anal. 
(C38H350 6N4P.HC1.l/3H20) C, H, N. 
20 EXAMPLE 26 
Synthesis of Derivatives of OrnP(OPh)2, LysP(OPh)2 and 
HomoLysP(OPh)2 (General Procedure C). The general pro-
cedures for synthesizing peptidyl phosphonate derivatives of 
lysine and homolysine follows: the blocked phosphonate 
25 Cbz-Lys(Phtt(OPh)2 (1 mmol) or Cbz-HomoLys(Phtt 
(0Ph)2 (1 mmol) were dissolved in 20 mL 30% HEr in 
acetic acid at room temperature. After 30 min, the acetic acid 
was removed under reduced pressure. The residue was 
triturated in Et20 to obtain HEr-H-Lys(Phtt(OPh)2 or 
30 HEr.H-HomoLys(Phtt(OPh)2. A mixture of HEr.H-Lys 
(Phtt(OPh)2 (1 mmol) or HEr.H-HomoLys(Phtt(OPh)2 (1 
mmol), HOEt (0.6 mmol) and an amino acid or peptide 
component (1.2 mmol) were added to S mL dry DMF 
followed by addition of Et3N (1.2 mmol). EDC (1.4 mmol) 
35 was then added at 0° C. and the reaction mixture was 
allowed to stir overnight at 2° C. Any precipitate that formed 
was removed by filtration followed by evaporation of the 
solvent under reduced pressure. The residue was redissolved 
in 60 mL EtOAc and washed with SO mL 0.6 M HCl, water, 
40 and 6% NaHC03, respectively. The solution was dried over 
Na2S04, the solvent removed, and the crude product purified 
by column chromatography (silica gel, elution with 
CHC13,Et0Ac=l:l). The purified peptidyl-Lys(Phtt(OPh)2 
(0.3 mmol) or peptidyl-HomoLys(Phtt(OPh)2 (0.3 mmol) 
45 was dissolved in 6 mL of isopropanol followed by addition 
of anhydrous hydrazine (0.9 mmol). The reaction mixture 
was stirred overnight at room temperature, a white precipi-
tate was removed by filtration, and the solvent was evapo-
rated. The residue was taken up in SO mL of CHC13, the 
50 solution was washed with 3x30 mL water and dried over 
Na2S04. Gaseous HCl was then bubbled through the chlo-
roform solution for 3 min. The final product was obtained by 
triturating the residue with ether after removal of the CHC13. 
Some of the derivatives of peptidyl-LysP(OPh)2 or peptidyl-
55 HomoLysP(OPh)2 were found to contain small amount of 
N2H4.HC1 as a byproduct. The NMR spectra shown a small 
peak at around ll 7.0 which is identical to an authentic 
sample confirming the existence of the salt. These lysine or 
homolysine phosphonate derivatives were used without fur-
60 ther purification. 
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All final products were characterized by NMR, mass 
spectroscopy (MS) or high resolution MS and elemental 
analysis. 
EXAMPLE 27 
Dip hen yl N -E enzylo xyc arb on ylamino -( 3-
amidinophenyl)methanephosphonate Hydrochloride { Cbz-
5,952,307 
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(3-AmPhGlyt(OPh)2}. This compound was synthesized by 
general procedure A starting with 3-cyanobenzaldehyde. 
Ethanol was used as solvent instead of methanol when 
synthesizing the iminoester. The product was obtained as a 
white solid: mp 87-89° C.; yield, 84%; 1H NMR (DMSO- 5 
d6) ll 5.0-5.2 (m, 2H), 5.6-5.8 (m, lH), 7.0-7.4 (m, 16H), 
7.7-7.8 (m, 3H), 8.0 (s, lH), 8.9-9.4 (m, 4H); HRMS 
(FAE+) m/z calcd. for C28H27N30 5ClP (M+Ht516.1688, 
found 516.1688. Anal. (C28H26N30 5ClP.HCl.H20) C, H, N. 10 
EXAMPLE 28 
Di-p-chlorophenyl N-Benzyloxycarbonylamino-( 4-
amidinophenyl)methanephosphonate Hydrochloride { Cbz- 15 ( 4-AmPhGlyt(OPh-p-Cl)2}. This compound was synthe-
sized starting with tri-para-chlorophenylphosphite. DMF 
was used at the amidination stage to prevent transesterifi-
cation which occurred when MeOH was used as the solvent. 
The product was obtained as a white solid: mp 123-130° C.; 20 
yield, 66%; 1H NMR (DMSO-d6) ll 5.0--5.2 (q, 2H), 5.7-5.9 
(m, lH), 7.0-8.0 (m, SH), 9.0-9.4 (m, 4H); HRMS (FAE+) 
m/z calcd. for C28H25N30 5Cl2P (M+Ht584.0909, found 
24 
under reduced pressure. The residue was taken up in 50 mL 
CHC13. After removal of the precipitate, the CHC13 was 
removed in vacuo. The residue was triturated in EtOAc to 
obtain the product as a white solid (0.38 g): mp 130-139° C.; 
yield, 80%; 1H NMR (DMSO-d6) ll 5.0 (m, 3H), 6.7 (m, 
lH), 7.0-7.4 (m, lOH), 7.5 (m, 4H), 7.7-7.8 (m, 2H), 8.3 (s, 
2H), 9.5 (s, lH); MS (FAE+) m/z 440.1 (M+Ht. Anal. 
(C22H250 5N3P.HC1.0.6H20) C, H, N. 
Cbz-( 4-AmPhGlyt(OPh)(OH) can be converted into 
Cbz-( 4-AmPhGlyt(OPh)(F) by reaction with SOC12 to give 
the chloro derivative followed by treatment with KF. 
EXAMPLE 30 
Diphenyl l-(N-(2-Phenoxybenzoylprolyl)amino )-5-
aminop en tane p hosp hon ate Hydrochloride { (2-
Phenoxybenzoyl-Pro-LysP(OPh)2}. This product was pre-
pared by general procedure C. The final product was 
obtained as a white solid containing a small amount of 
N2H4.HC1 as a byproduct: mp 87-89° C.; yield, 93%; 1H 
NMR (DMSO-d6) ll 1.3-2.0 (m, lOH), 2.7 (m, 2H), 3.4 (m, 
2H), 4.4--4.6 (m, 3H), 7.0-7.5 (m, 19H), 7.7-7.9 (br s, 3H); 
HRMS (FAE+) m/z calcd. for C35H39N30 6P (M+Ht 
628.2576, found 628.2652; HPLC (90% CH3CN/H20 and 584.0934. Anal. (C28H24N30 5ClP.HCl.H20) C, H, N. 
25 10% CH3CN/H20) major peak (>90%) with several 
EXAMPLE 29 
Methyl Phenyl N-Benzyloxycarbonylamino-( 4-
amidinophenyl)methanephosphonate Hydrochloride { Cbz-
byproducts, tR=l2.8 min. Anal. 
(C35H38N30 6P.l.3HC1.0.4H20.0.3N2H4) C, H, N. 
EXAMPLE 31 
Diphenyl l-(N-(3-Phenoxybenzoylprolyl)amino )-5-
aminop en tane p hosp hon ate Hydrochloride {(3-
Phenoxybenzoyl)-Pro-LysP(OPh)2}. This product was pre-
pared by general procedure C. The final product was 
obtained as a white solid containing a small amount of 
N2H4.HC1 as a byproduct: mp 85-87° C.; yield, 91 %; 1H 
NMR (DMSO-d6) ll 1.3-2.1 (m, lOH), 2.7(m, 2H) 3.4 (m, 
2H), 4.4--4.6 (m, 3H), 7.0-7.5 (m, 19H), 7.7-7.9 (br s, 3H); 
HRMS (FAE+) m/z calcd. for C35H39N30 6P (M+Ht 
626.2576, found 628.2515; HPLC (90% CH3CN/H20 and 
( 4-AmPhGlyt{OPh)(OMe)}. Cbz-(4-CNPhGlyt(OPh)2 (1 30 
mmol) was dissolved in 45% MeOH in CHC13. The solution 
was saturated with gaseous HCl at 0° C. The reaction 
mixture was allowed to stir overnight followed by the 
removal of solvent on a rotary evaporator at 20° C. The 35 
residue was triturated in Et20. The solid obtained was 
redissolved in 100 mL MeOH. The methanol solution was 
then saturated with gaseous NH3. The reaction mixture was 
stirred at 0° C. for one hour and the solvent was evaporated 
under reduced pressure. Fresh methanol (100 mL) was then 
added to the residue and the solution was stirred for one day 
40 10% CH3CN/H20) major peak (>90%) with several 
at 50° C. The methanol was then removed followed by the 
addition of CHC113 (100 mL). Gaseous HCl was bubbled 
through the solution for 5 min at 0° C. After removal of the 
CHC13, the residue was triturated in Et20. The product was 45 
obtained as a white solid and used without further purifica-
tion: mp 100-106° C.; yield, 46%; 1H NMR (DMSO-d6) ll 
3.5-3.7 (m, 3H), 5.0--5.2 (m, 2H), 5.5 (m, lH), 7.0-7 (m, 
12H), 7.6-8.0 (m, 4H), 8.8-9.4 (m, 4H); HRMS (FAE+) m/z 
calcd. for C23H240 5N3P (M+Ht454.1532, found 454.1515; 50 
HPLC (90% CH3CN/H20 and 10% CH3CN/H20) single 
peak (>95%) with traces of three byproducts, tR=ll.6 min. 
Anal. (C23H24N30 5P.HC1.0.5Et20) C, H, N. 
byproducts, tR= 13 .2 min. Anal. 
(C35H38N30 6P.l.2HCLH20.0.2N2H4) C, H, N. 
EXAMPLE 32 
Diphenyl l-(N-(2-Phenoxybenzoylprolyl)amino )-6-
am ino hexane p hosp hon ate Hydrochloride {(2-
Phenoxybenzoy 1)-Pro-HomoLysP ( 0 Ph )J. This product was 
prepared by general procedure C. The final product was 
obtained as a white solid containing a small amount of 
N2H4.HC1 as a byproduct: mp 83-85° C.; yield, 42%; 1H 
NMR (DMSO-d6) ll 1.2-2.0 (m, 12H), 2.7 (m, 2H), 3.5 (m, 
2H), 4.2-4.7 (m, 2H), 6.9-7.5 (m, 21H), 7.7-7.9 (br s, 3H); 
HRMS (FAE+) m/z calcd. for C36H41N30 6P (M+Ht 
EXAMPLE 30 
Phenyl Hydrogen N-Benzyloxycarbonylamino-(4-
amidinophenyl)methanephosphonate Hydrochloride { Cbz-
55 642.2733, found 642.2727; HPLC (90% CH3CN/H20 and 
10% CH3CN/H20) two major peaks (diastereomers, 1:0.3) 
with a trace of byproducts ( <5% ), tR=l2.8, 13.0 min. Anal. 
(C36H40N30 6P.l.3HC1.0.4H20.0.3N2H4) C, H, N. 
( 4-AmPhGly)P(OPh)(OH)}. The phosphonate Cbz-(4-
AmPhGly)P(OPh)2 (0.55 g, 1.0 mmol) and cis- 60 
dicyclohexane 18-crown-6 (0.037 g, 0.1 mmol) were 
dissolved in 10 mL of a mixture of DMF/water (80%, v/v) 
followed by addition of a 30% ammonia solution (0.16 mL, 
2.6 mmol). The reaction mixture was allowed to stir for 3 
days. The reaction was monitored by TLC (silica gel, 65 
CHCl3,MeOH:HOAc=8:2:0.2). A solution of 2 M HCl (1.4 
mL, 2.8 mmol) was added and the solvent was evaporated 
EXAMPLE 33 
Diphenyl l-(N-(3-Phenoxybenzoylprolyl)amino )-6-
am ino hexane p hosp hon ate Hydrochloride {(3-
Phenoxybenzoy 1)-Pro-HomoLysP ( 0 Ph )J. This product was 
prepared by general procedure C. The final product was 
obtained as a white solid containing a small amount of 
N2H4.HC1 as a byproduct: mp 79-84° C.; yield, 38%; 1H 
NMR (DMSO-d6) ll 1.1-1.9 (m, 12H), 2.7 (br s, 2H), 
5,952,307 
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3.4-3.6 (m, 2H), 4.2-4.6 (m, 2H), 7.0--7.5 (m, 21H), 7.9 (br 
s, 3H); HRMS (FAE+) m/z calcd. for C36H41 N3 0 6P (M+Ht 
642.2733, found 642.2768; HPLC (90% CH3 CN/H2 0 and 
10% CH3 CN/H2 0) two major peaks (diastereomers, 1:0.5) 
with several byproducts ( <10% ), tR=ll.6, 13.6 min. Anal. 5 
(C36H40N3 0 6P.1.3HC1.0.5H2 0.0.3N2H4 ) C, H, N. 
It is obvious that those skilled in the art may make 
modifications to the invention without departing from the 
spirit of the invention or the scope of the subjoined claims 
and their equivalents. 
TABLE I 
Inhibition of Trypsin-like Serine Proteases by 4-Amidinophenylglycine Phosphonate Diphenyl Ester Derivatives' 
R~ 
Cbz 
Sue 
trans-Cinnamoyl 
3-(2-Furyl)acryloyl 
3-(2-Thienyl)acryloyl 
trans-3-(3-Pyridyl)acryloyl 
3-Phenoxybenzoyl 
2-Phenoxybenzoyl 
1-NpS02 
1-Naphthylmethoxycarbonyl 
Cbz-Ala 
Cbz-Val 
Cbz-Leu 
Cbz-Pro 
Cbz-Thr 
Cbz-Lys 
Cbz-Phe 
(2-Phenoxybenzoyl)-Pro 
(3-Phenoxybenzoyl)-Pro 
(3,3-Diphenylpropanoyl)-Pro 
(3-Phenylpropanoyl)-Pro 
Cbz-Ala-Ala 
Sue-Ala-Ala 
Cbz-Pro-Ala 
Cbz-Asp-Ala 
Cbz-Asp(t-Bu)-Ala 
Cbz-Lys-Ala 
Cbz-Lys(Boc )-Ala 
Cbz-Phe-Ala 
Boc-0-Phe-Pro 
Ph---CH2-S02---Gly-Pro 
Cbz-Ala-Ala-Ala 
R-HN 
0 
11,....oPh 
p 
'-oPh 
H1N NH/ 
k /! M-1s-1 
human rat rat 
granzyme A granzyme A granzyme K 
1180 3.8 ± 0.7 
857 0.3 ± 0.07 
400 ± 10 340 ± 18 3 
1740 ± 41 1740 ± 237 32 
740 ± 18 430 ± 31 4 
5 1 3 
340 ± 53 470 ± 14 
540 ± 3 340 ± 1 
330 ± 26 30 ± 1 NI 
160 ± 2 90 ± 9 12 
1670 ± 11 1270 ± 85 NI 
6.7 ± 0.1 0.7 ± 0.04 
6.3 ± 0.7 NI 
790 ± 17 34 ± 4 
2220 ± 40 3 
30 ± 1 15 ± 1 
14 ± 1 8 13 
610 ± 88 60 ± 5 
330 ± 58 NI 
250 ± 8 1830 ± 140 
1510 ± 217 50 ± 2 
820 ± 29 480 ± 27 5 
260 ± 15 0.3 ± 0.01 
380 ± 18 5 
240 ± 5 
280 ± 5 NI 
90 ± 9 NI 
110 ± 5 NI 
1770 ± 13 4.2 ± 0.3 
170 56 ± 2 
3650 ± 180 87 
730 ± 15 590 ± 17 7 
mast cell bovine 
tryptase trypsin 
0.6 2000 
0.2 45 ± 3 
0.3 110 ± 1 
Nib 360 ± 28 
1 300 ± 22 
NI NI ct 
NI 50 ± 2 
0.4 670 ± 53 
10 170 ± 34 
NI 30 ± 1 
0.8 1850 ± 85 
21.2 ± 0.2 41 ± 3 
0.3 50 ± 1 
1.2 910 ± 81 
NI 97 
NI 30 ± 1 
5% Inh 17 ± 1 
0.9 7760 ± 310 
7% Inh 4080 ± 32 
NI 2660 ± 40 
0.4 1520 ± 27 
2 3620 ± 588 
0.7 640 ± 36 
240 ± 10 
0.7 2550 ± 145 
3 2000 ± 24 
2 3140 ± 262 
8.5 ± 0.4 3100 ± 177 
4 3010 ± 318 
0.4 130b 
2 37060 ± 986 
2 1780 ± 33 
26 
'Inhibition constants were measured in O.lM Hepes, O.OlM CaCl0o pH 7.5 for trypsin, granzymes A, and K, and in O.lM 
Hepes, 10% glycerol, 10 mM heparin, pH 7.5 for mast cell tryptase, and at 25° C. The reaction mixtures contained 2% 
DMSO for trypsin, 7.6% for granzyme A, and 7.1 % for granzyme Kand tryptase. The substrate was Z-Arg-SBzl for 
granzymes and trypsin, and Z-Arg-SBzl or Z-Lys-SBzl for tryptase in the presence of DTNB. The inhibitor 
concentration ranged from 0.001 to 100 µM. 
bNI, no inhibition after 25 min of incubation with enzyme. 
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TABLE II 
Inhibition of Thrombin and Other Trypsin-like Enzymes by Derivatives of (4-AmPhGly)"(OPh)2 ' 
1'abJ[I] (M-'s-1) 
Inhibitor human thrombin bovine trypsin mast cell tryptase factor Xa 
Cbz-(4-AmPhGly)"(OPh)2 sob 170b 0.6 
Cbz-(3-AmPhGly)"(OPh)2 50% Inh NI NI 
Cbz-(4-AmPhGly)"(OPh-p-Cl)2 9,300 ± 210 41,100 ± 5400 3 ± 0 
Cbz-(4-AmPhGly)"(OPh)(OMe) 41 83 
Cbz-(4-AmPhGly)"(OPh)(OH) NI 0.3 NI 
Suc-(4-AmPhGly)P(OPh)2 2 45 ± 3 0.2 
trans-Cinnamoyl-( 4-AmPhGly)"(OPh)2 20 ± 1 110 ± 1 0.3 
(2-Furyl)acryloyl-( 4-AmPhGly )P(OPh)2 15 ± 1 360 ± 28 NI 
3-(2-Thienyl)acryloyl-(4-AmPhGly)"(OPh)2 90 ± 4 300 ± 22 
3-(3-Pyridyl)acryloyl-(4-AmPhGly)"(OPh)2 2 NI NI 
4-Phenylbutanoyl-(4-AmPhGly)"(OPh)2 17 ± 1 15% Inh 
2-Phenoxybeuzoyl-( 4-AmPhGly )P(OPh)2 270 ± 20 670 ± 53 0.4 
3-Phenoxybeuzoyl-( 4-AmPhGly )"(0Ph)2 200 ± 8 50 ± 2 NI 
1-Naphthyloxycarbonyl-( 4-AmPhGly )" (0Ph)2 30 ± 2 30 ± 1 NI 
Tolyl-SOr(4-AmPhGly)"(OPh)2 94 ± 26 35 ± 6 
1-NpSOr( 4-AmPhGly)P (0Ph)2 24 ± 3 170 ± 34 10 ± 1 
Cbz-Gly-( 4-AmPhGly)"(OPh)2 24 ± 3 195 ± 9 
Cbz-Ala-(4-AmPhGly)"(OPh)2 750 ± 18 1,850 ± 85 0.8 
Cbz-Val-(4-AmPhGly)"(OPh)2 5.5 ± 0.4 18 ± 2 21.2 ± 0.2 
Cbz-Leu-(4-AmPhGly)P(OPh)2 19% Inh 1.3 ± 0.1 0.3 
Boc-Ser-(4-AmPhGly)"(OPh)2 31 ± 2 20 ± 1 3.5 ± 0.4 
Cbz-Thr-(4-AmPhGly)P(OPh)2 61 ± 3 97 ± 2 NI 
Cbz-Lys-(4-AmPhGly)"(OPh)2 88 ± 2 30 ± 1 NI 
Cbz-Phe-(4-AmPhGly)P(OPh)2 20 ± 1 17 ± 1 5% Inh 
Cbz-Trp-(4-AmPhGly)"(OPh)2 1.2 ± 0.0 0.6 
Cbz-Pro-(4-AmPhGly)P(OPh)2 640 ± 86 910 ± 81 
2-Phenoxybeuzoyl-Pro-( 4-AmPhGl y)"(OPh) 2 42,400 ± 4190 7,760 ± 310 0.9 
3-Phenoxybeuzoyl-Pro-( 4-AmPhGl y)P (0Ph)2 1,340 ± 225 4,080 ± 32 7% Inh 
3-Phenylpropanoyl-Pro-( 4-AmPhGly )"(0Ph)2 6,070 ± 68 1,520 ± 27 0.4 
3,3-Diphenylpropanoyl-Pro-( 4-AmPhGly)P (0Ph)2 80,300 ± 368 2,660 ± 40 NI 
Boc-D-Leu-Gly-(4-AmPhGly)"(OPh)2 1,187 ± 76 2,960 ± 300 10 ± 0.4 
Boc-0-Phe-Gly-( 4-AmPhGly)P (0Ph)2 2,225 ± 106 6,620 ± 835 2.8 ± 0 
Cbz-Glu-Gly-( 4-AmPhGly)"(OPh)2 46 ± 5 70 ± 5 1.4 ± 0.1 
Cbz-Ala-Ala-(4-AmPhGly)P(OPh)2 3,030 ± 222 3,620 ± 588 2 ± 0 
Suc-Ala-Ala-(4-AmPhGly)"(OPh)2 2 640 ± 36 0.7 
Cbz-Pro-Ala-(4-AmPhGly)P(OPh)2 70 ± 2 240 ± 10 1 ± 0 
Cbz-Asp-Ala-(4-AmPhGly)"(OPh)2 110 ± 12 2,550 ± 145 
Cbz-Asp(O-t-Bu)-Ala-(4-AmPhGly)"(OPh)2 480 ± 93 2,000 ± 24 3 ± 0 
Cbz-Lys-Ala-(4-AmPhGly)"(OPh)2 180 ± 7 3,140 ± 262 2.0 ± 0.0 
Cbz-Lyz(Boc)-Ala-(4-AmPhGly)"(OPh)2 450 ± 58 3,100 ± 177 8.7 ± 0.4 
Cbz-Phe-Ala-(4-AmPhGly)"(OPh)2 1,150 ± 88 3,010 ± 318 4.0 ± 0.3 
Boc-Val-Val-(4-AmPhGly)P(OPh)2 85 ± 5 61 ± 5 
Boc-D-Phe-Val-(4-AmPhGly)"(OPh)2 63 ± 4 30 ± 2 
Boc-0-Phe-Leu-( 4-AmPhGly )P(OPh)2 921 ± 44 24 ± 2 1.4 ± 0.4 
Boe-Leu-Ser-( 4-AmPhGly)"(OPh)2 97 ± 2 177 ± 2 
Boc-D-Phe-Pro-(4-AmPhGly)P(OPh)2b 11,000 2,200 
PhCH2S02-Gly-Pro-(4-AmPhGly)"(OPh)2 17,200 ± 128 37,060 ± 986 2.0 ± 0.1 
Leu-Thr-(4-AmPhGly)"(OPh)2 58 ± 3 24.5 ± 0.0 
Boc-Leu-Thr-(4-AmPhGly)"(OPh)2 75 ± 1 35 ± 6 
Cbz-Ala-Ala-Ala-(4-AmPhGly)P(OPh)2 1,290 ± 26 1,780 ± 33 2.0 ± 0.2 
Leu-Asp-Pro-(4-AmPhGly)"(OPh)2 65 ± 1 204 ± 19 1.3 ± 0.2 
Boc-Leu-Asp(O-t-Bu)-Pro-(4-AmPhGly)"(OPh)2 502 ± 21 670 ± 53 8 ± 1 
Boc-Asn-Leu-Thr-(4-AmPhGly)"(OPh)2 46 ± 6 18 ± 2 
'Enzyme was incubated with the inhibitor in 250 µL of the proper buffer at 25° C. Specifically, the inhibition reation mixtures were 
composed of: 0.13 µM trypsin, 0.25-42 µM inhibitor in an 80 mM Hepes, pH 7.5 buffer containing 1 mM CaC12 and 8% DMSO; 
0.07 µM thrombin, 0.25-42 µM inhibitor in an 80 mM Hepes, pH 7.5 buffer containing 428 mM NaCl and 8% DMSO; 0.07 µM 
tryptase, 20-66 µM inhibitor in an mM Hepes, pH 7.5 buffer containing 8 mM heparin, 166 mM NaCl, 0.8 mM Mes, 9% glycerol 
and 8% DMSO; 0.42 µM factor Xa, 66 µM inhibitor in an 80 mM Hepes, pH 7.5 buffer containing 428 mM NaCl and 8% DMSO. 
Aliquots of 25 µL were withdrawn at various intervals and the residual enzymatic activity was measured as described in 
experimental section. The kobs values were calculated from pseudo-first-order plots. 
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TABLE III 
Inhibition of Thrombin and Other Try2sin-like Enzymes by Derivatives of Lysine Phos2honates' 
I M-1s-1 
Inhibitor human thrombin bovine trypsin plasmin um kinase mast cell tryptase 
Cbz---OrnP(OPh)2 NI NI NI NI NI 
Cbz-LysP(OPh)2 17 6,235 8.2 ± 0.4 15 ± 2 17 ± 1 
2-Phenoxybenzoyl-Pro-LysP(OPh)2 4,531 ± 140 16,411 ± 460 7.1 ± 0.2 0.6 ± 0.1 19 ± 1 
3-Phenoxybenzoyl-Pro-LysP(OPh)2 1,142 ± 52 19,380 ± 300 7.4 ± 0.6 1.6 ± 0.1 16 ± 1 
3,3-Diphenylpropanoyl-Pro-LysP(OPh)2 27,450 ± 803 14,447 ± 905 7.0 ± 0.2 1.5 ± 0.0 74 ± 9 
Cbz-Thr-LysP(OPh)2 NI 230 0.7 ± 0.1 7±1 
Boc-Asn-LysP(OPh)2 NI 3 NI NI 
Boc-Lys(Cbz)-LysP(OPh)2 NI NI NI NI 
Boc-D-Phe-Pro-LysP(OPh)2 9,364 ± 110 28,840 ± 1,800 51 ± 4 38 ± 3 68 ± 4 
Suc-Val-Pro-LysP(OPh)2 3.4 ± 0.4 416 ± 28 NI 0.6 
PhCH2S02--Gly-Pro-LysP(OPh)2 649 ± 14 12,472 ± 1,400 13 ± 1 39 ± 2 24 ± 0 
Cbz-HomoLysP(OPh)2 NI 21 ± 6 NI 1.0 ± 0.0 0.7 
2-Phenoxybenzoyl-Pro-HomoLysP(OPh)2 57 ± 5 69 ± 13 3.6 ± 0.4 24 ± 4 7.7 ± 0.3 
3-Phenoxybenzoyl-Pro-HomoLysP(OPh)2 27 ± 5 116 ± 34 4.6 ± 0.1 22 ± 1 10 ± 3 
3,3-Diphenylpropanoyl-Pro-HomoLysP(OPh)2 224 ± 8 16 ± 1 50% Inhb 2.1 ± 0.2 1.1 ± 0.0 
D-Phe-Pro-HomoLysP(OPh)2 1,342 ± 272 164 ± 14 NI 7.8 ± 0.0 4.1 0.2 
Suc-Val-Pro-HomoLysP(OPh)2 1.6 ± 0.3 51±10 NI NI 4.1 ± 0.4 
PhCH2S02Gly-Pro-HomoLysP(OPh)2 137 ± 12 528 ± 59 8.4 ± 0.2 38 ± 3 32 ± 2 
'Enzyme (0.06-0.5 µM) was incubated with the inhibitor (0.25-42 µM) in 250 µL of the proper buffer containing 9% DMSO at 25° 
C. The final inhibition reaction mixtures are given in the footnote to Table 1. Aliquots of 25 µL were withdrawn at various intervals 
and the residual enzymatic activity was measured as described in experimental section. The kobs values were calculated from 
~seudo-first-order plots. 
Inhibitor concentration of 0.24 mM. 
SEQUENCE LISTING 
(1) GENERAL INFORMATION: 
(iii) NUMBER OF SEQUENCES: 
(2) INFORMATION FOR SEQ ID NO:l: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 4 amino acids 
(B) TYPE: amino acid 
(D) TOPOLOGY: linear 
(ii) MOLECULE TYPE: peptide 
(iii) HYPOTHETICAL: no 
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: 
Ala Ala Pro Met 
1 
(2) INFORMATION FOR SEQ ID N0:2: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 4 amino acids 
(B) TYPE: amino acid 
(D) TOPOLOGY: linear 
(ii) MOLECULE TYPE: peptide 
(iii) HYPOTHETICAL: no 
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:2: 
Lys Val Pro Val 
1 
(2) INFORMATION FOR SEQ ID N0:3: 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 4 amino acids 
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-continued 
(B) TYPE: amino acid 
(D) TOPOLOGY: linear 
(ii) MOLECULE TYPE: peptide 
(iii) HYPOTHETICAL: no 
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:3: 
Ala Ala Pro Leu 
What is claimed is: 
1. A compound of the formula: 
R 
~/oz 
X-AA3-AA2-N P 
H 11'z1 
0 
or a pharmaceutically acceptable salt thereof, wherein: 
15 
20 
R is selected from the group consisting of phenyl substi-
tuted with B, benzyl substituted with B on the phenyl 25 
ring, and C1 _6 alkyl substituted with B, 
B is selected from the group consisting of amidino 
{-C(=NH)NH2 }, guanidino {-NH-C(=NH) 
NH2 }, isothiureido {-S-C(=NH)NH2 }, and amino, 
Z is selected from the group consisting of C1 _6 30 
perfiuoroalkyl, phenyl, phenyl monosubstituted with J, 
phenyl disubstituted with J, and phenyl trisubstituted 
with J, 
Z1 is selected from the group consisting of cl-6 
perfiuoroalkoxy, phenoxy, phenoxy monosubstituted 35 
with J, phenoxy disubstituted with J, phenoxy trisub-
stituted with J, cl-6 alkoxy, and halogen, 
J is selected from the group consisting of halogen, C1 _6 
alkyl, C1 _6 perfiuoroalkyl, C1 _6 alkoxy, N02 , CN, OH, 40 C02H amino, C1 _6 alkylamino, C2 _12 dialkylamino, 
C1 _6 acyl, C1 _6 alkoxy-CO-, and C1 _6 alkyl-S-, 
AA3 and AA2 are the same or different and are selected 
from the group consisting of 
(a) a single bond, and 45 (b) a blocked or unblocked amino acid residue with the 
Lor D configuration at the a-carbon carbon selected 
from the group consisting of alanine, valine, leucine, 
isoleucine, praline, methionine, methionine 
sulfoxide, phenylalanine, tryptophan, serine, 50 
threonine, cysteine, tyrosine, asparagine, glutamine, 
aspartic acid, glutamic acid, lysine, arginine, 
histidine, phenylglycine, norleucine, norvaline, 
alpha-aminobutyric acid, citrulline, hydroxyproline, 
omithine, homolysine, and homoarginine, and 55 (c) glycine, sarcosine, epsilon-aminocaproic acid, and 
beta-alanine, 
X is selected from the group consisting of Y-CO- and 
Y-502-, 
Y is selected from the group consisting of 60 
(a) C 6 H 5-CH=CH-, (2-furyl)-CH=CH-, 
(2-thienyl)-CH=CH-, and (2-pyridyl)-
CH=CH-, 
(b) cl-6 alkenyl substituted with a heterocyclic group, 
(c) C1 _6 alkenyl substituted with a moiety selected from 65 
the group consisting of phenyl, phenyl monosubsti-
tuted with K, phenyl disubstituted with K, phenyl 
trisubstituted with K, naphthyl, naphthyl monosub-
stituted with K, naphthyl disubstituted with K, and 
naphthyl trisubstituted with K, 
(d) 2-phenoxyphenyl and 3-phenoxyphenyl, 
(e) Phenyl substituted with a moiety selected from the 
group consisting of phenoxy, phenoxy monosubsti-
tuted with K, phenoxy disubstituted with K, phenoxy 
trisubstituted with K, naphthyloxy, naphthyloxy 
monosubstituted with K, naphthyloxy disubstituted 
with K, and naphthyloxy trisubstituted with K, and 
K is selected from the group consisting of halogen, C1 _6 
alkyl, C1 _6 perfiuoroalkyl, C1 _6 alkoxy, N02 , C02 H, 
amino, cl-6 alkylamino, c2-12 dialkylamino, cl-6 acyl, 
C1 _6 alkoxy-CO-, and C1 _6 alkyl-S-. 
2. A compound according to claim 1 wherein R is selected 
from the group consisting of 
(a) 3-amidinophenyl, 
(b) 4-amidinophenyl, 
(c) 3-amidinobenzyl, 
( d) 4-amidinobenzyl, 
( e) 3-guanidinophenyl, 
(t) 4-guanidinophenyl, 
(g) 3-guanidinobenzyl, and 
(h) 4-guanidinobenzyl. 
3. A compound according to claim 2 wherein 
AA2 is an amino acid residue selected from the group 
consisting of alanine, glycine, isoleucine, leucine, 
praline, phenylalanine, threonine, serine, and valine, 
AA3 is selected from the group consisting of 
(a) a single bond, 
(b) an amino acid residue selected from the group 
consisting of alanine, glycine, isoleucine, leucine, 
plienylalanine, and valine, 
Xis Y-CO-, 
Y is selected from the group consisting of 
(a) C 6 H 5-CH=CH-, (2-furyl)-CH=CH-, 
(2-thienyl)-CH=CH-, and (2-pyridyl)-
CH=CH-, 
(b) cl-6 alkenyl substituted with a heterocyclic group, 
(c) C1 _6 alkenyl substituted with a moiety selected from 
the group consisting of phenyl, phenyl monosubsti-
tuted with K, phenyl disubstituted with K, phenyl 
trisubstituted with K, naphthyl, naphthyl monosub-
stituted with K, naphthyl disubstituted with K, and 
naphthyl trisubstituted with K, 
(d) 2-phenoxyphenyl and 3-phenoxyphenyl, 
(e) Phenyl substituted with a moiety selected from the 
group consisting of phenoxy, phenoxy monosubsti-
tuted with K, phenoxy disubstituted with K, phenoxy 
trisubstituted with K, naphthyloxy, naphthyloxy 
monosubstituted with K, naphthyloxy disubstituted 
with K, and naphthyloxy trisubstituted with K, and 
K is selected from the group consisting of halogen, C1 _6 
alkyl, C1 _6 perfiuoroalkyl, C1 _6 alkoxy, N02 , CN, OH, 
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C02H, amino, C1 _6 alkylamino, C2 _12 dialkylamino, 
C1 _6 acyl C1 _6 alkoxy-CO-, and C1 _6 alkyl-S-. 
4. A compound according to claim 1 wherein R is selected 
from the group consisting of 
(a) -CH2 CH2 CH2NH-C(=NH)NH2 , 
(b) -CH2 CH2 CH2 CH2 NH2 , 
(c) -CH2 CH2 CH2 NH2 , and 
(d) -CH2 CH2 CH2 CH2 CH2 NH2 . 
5. A compound according to claim 4 wherein 
AA2 is an amino acid residue selected from the group 
consisting of alanine, glycine, isoleucine, leucine, 
praline, phenylalanine, threonine, serine, and valine, 
AA3 is selected from the group consisting of 
(a) a single bond, 
(b) an amino acid residue selected from the group 
consisting of alanine, glycine, isoleucine, leucine, 
phenylalanine, and valine, 
XisY-CO-, 
Y is selected from the group consisting of 
(a) C 6 H 5-CH=CH-, (2-furyl)-CH=CH-, 
(2-thienyl)-CH=CH-, and (2-pyridyl)-
CH=CH-, 
(b) cl-6 alkenyl substituted with a heterocyclic group, 
(c) C1 _6 alkenyl substituted with a moiety selected from 
the group consisting of phenyl, phenyl monosub-
stitued with K, phenyl disubstituted with K, phenyl 
trisubstituted with K, naphthyl, naphthyl monosub-
stituted with K, naphthyl disubstituted with K, and 
naphthyl trisubstituted with K, 
(d) 2-phenoxybenzoyl and 3-phenoxybenzoyl, 
( e) Phenyl substituted with a moiety selected from the 
group consisting of phenoxy, phenoxy monosubsti-
5 
10 
15 
20 
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tuted with K, phenoxy disubstituted with K, phenoxy 
trisubstituted with K, naphthyloxy, naphthyloxy 
monosubstituted with K, naphthyloxy disubstituted 
with K, and naphthyloxy trisubstituted with K, and 
K is selected from the group consisting of halogen, C1 _6 
alkyl, C1 _6 perfiuoroalkyl, C1 _6 alkoxy, N02 , CN, OH, 
C02H, amino, C1 _6 alkylamino, C2 _12 dialkylamino, 
C1 _6 acyl, C1 _6 alkoxy-CO-, and C1 _6 alkyl-S-. 
6. A compound selected from the group consisting of: 
(a) Cinnamoyl-( 4-AmPhGlyt(OPh)2 , 
(b) 3-(2-Furyl)acryloyl-( 4-AmPhGlyt{OPh)2 , 
( c) 3-(3-Thienyl)acryloyl-( 4-AmPhGlyt{OPh)2 , 
( d) 3-(2-Pyridyl)acryloyl-( 4-AmPhGlyt{OPh)2 , 
(e) 2-Phenoxybenzoyl-( 4-AmPhGlyt(OPh)2 , 
(t) 3-Phenoxybenzoyl-( 4-AmPhGlyt(OPh)2 , 
(g) 2-Phenoxybenzoyl-Pro-(4-AmPhGlyt(OPh)2 , 
(h) 3-Phenoxybenzoyl-Pro-(4-AmPhGlyt(OPh)2 , 
(i) 2-Phenoxybenzoyl-Pro-LysP(OPh)2 , 
G) 3-Phenoxybenzoyl-Pro-LysP(OPh)2 , 
(k) 2-Phenoxybenzoyl-Pro-HomoLysP(OPh)2 , and 
(1) 3-Phenoxybenzoyl-Pro-HomoLysP(OPh)2 . 
25 7. A process for inhibiting serine protease activity com-
prising the step of adding to a medium containing the 
protease that amount of the compound of claim 1 effective 
to inhibit said activity. 
8. A method of decreasing blood coagulation comprising 
30 the administration to a mammalian species in need of such 
treatment a therapeutically effective amount of the com-
pound of claim 1. 
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